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Most commonly used adjuvants in vaccines are effective at elevating serum antibody 
titers but do not elicit significant CD4 or CD8 T cell response.	  CD4 T cells are important 
in protection against challenging infectious diseases such as HIV, malaria and 
tuberculosis and also important for anti-tumor immunity. Therefore, our goal is to 
evaluate how adjuvants lipopolysaccharide (LPS) and polyinosinic:polycytidilic acid 
(poly I:C) induced mechanisms enhance the CD4 T cell immunity. LPS, a known Toll 
like receptor 4 (TLR4) ligand, when injected with or shortly after a T cell antigen, 
enhances T cell clonal expansion, long-term survival and Th1 differentiation. 
Importantly, LPS can synergize with a potent costimulatory agonist, OX40/CD134 (anti-
CD134 mAb) to further enhance CD4 T cell expansion, survival, and memory. The 
mechanism behind this synergy is unknown. Our preliminary data suggests that Ag, 
LPS and anti-CD134 immunization results in enhanced production of type I IFN (IFN-β) 
which corresponds with the increased T cell expansion this vaccine induces. Therefore, 
we hypothesized that LPS and anti-CD134 mediated synergistic CD4 T cell response 
could depend on IFNαR signaling.  
Depending on the model used, we show that absence of IFNαR signaling results in 
minor to major reduction in specific CD4 T cell expansion in peripheral lymph node 
(pLN) and liver tissue.  
	  
	  
More importantly, LPS induced type I IFN, promotes synthesis of chemokines, CXCL9 
and CXCL10, suggesting their role in the LPS and CD134 costimulation response. 
Indeed, blocking CXCL9 highlighted the importance of this chemokine in promoting 
specific CD4 T cell accumulation in pLN and liver. CXCL9 impacted the T cell 
accumulation in spite of no difference in serum levels of type I IFN, suggesting that type 
I IFN induced downstream chemokines could play a more dominant role in promoting T 
cell accumulation.  
We next evaluated the role of synthetic dsRNA analog, poly I:C in enhancing CD4 T cell 
immunity. Recent studies, have shown that poly I:C synergizes with CD40 agonist Ab, 
to promote enhanced effector CD4 T cell response, where poly I:C induced IFNαR 
signaling was shown to enhance CD134L expression on dendritic cells (DC’s). 
Therefore, we hypothesized that poly I:C could be directly combined with CD134 
costimulation to promote enhanced CD4 T cell immunity. Indeed our results show that, 
administration of peptide Ag with poly I:C and anti-CD134 enhanced the Ag-specific 
CD4 expansion and Th1 differentiation and it was dependent on poly I:C induced IFNαR 
signaling. Thus, the vaccine combination of poly I:C and anti-CD134 should be 
evaluated for its efficacy in therapeutic vaccines against infectious diseases or cancer 
where CD4 Th1-type immunity is crucial. Additionally, we also show that CD134 
costimulation induced CD4 Th1 response was also dependent on IFNαR signaling. 
Understanding, the mechanism of how CD134 costimulation triggers IFNαR signaling to 
promote CD4 T cell response will be important for the efficient targeting of CD134 in 
preclinical cancer trials. 
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CHAPTER I: INTRODUCTION 
 
UNDERSTANDING HOW LPS AND POLY I:C INDUCED RESPONSES                             
IMPACT THE CD4 T CELL IMMUNITY 
 
(I) Use of Adjuvants in Vaccines 
Vaccines have been one of the most successful medical inventions that have led to eradication 
and protection against several infectious diseases in the last 100 years. Current vaccines 
make use of purified protein components of infectious organisms to produce more targeted 
immune response. However, the lack of the immunostimulatory components of the whole 
pathogen results in a weaker immune response. Hence, adjuvants are added to vaccines to 
intensify the host immune response against the infectious agent. Although adjuvants have 
been used in vaccines for the past century, few have been approved for use in humans. 
Aluminum salt in the form of aluminum hydroxide, aluminum phosphate or alum has been the 
predominant components used in licensed human vaccines such as hepatitis A and B, human 
papillomavirus (HPV) and diphtheria-tetanus-pertussis (DTP) [1-4]. Alum based adjuvants, 
predominantly induce Th2 response. However, vaccines against some of the major causes of 
mortality worldwide including malaria, human immunodeficiency virus  (HIV), tuberculosis, 
require a productive B-cell and T-cell response [5-7]. CD4 T cells are important in protection 
against these diseases as they can help B cells synthesize specific antibodies as well as 
stimulate cytotoxic T cells to kill the infected cells. Bacterial LPS, is one such adjuvant that 
enhances both humoral and T cell immunity [8, 9]. In terms of CD4 T cell response, LPS can 
enhance T cell clonal expansion, effector differentiation, and long-term survival [10, 11]. Such 
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an adjuvant could be beneficial in vaccines to induce long-term immunity to fight primary as 
well as secondary infections. The toxicity of LPS, however, prevents its human use. Pioneering 
work from Ribi, led to the development of a less toxic derivative of LPS, monophosphoryl lipid 
A (MPL) [12]. Although both LPS and MPL signal via TLR4, the latter signals mainly via TRIF 
[13] whereas the former signals via both MyD88 and TRIF, which results in enhanced 
proinflammatory cytokines and possible toxicity [13]. MPL formulated with alum (AS04), is now 
a component of licensed vaccines for HPV (Cervarix®) and Hepatitis B (Fendrix®) [14]. AS04 
stimulates a polarized Th1 cell response in contrast to the mixed Th1-Th2 cell response 
induced by alum alone [14]. Subsequent studies, investigating less toxic derivatives of LPS 
such as MPL and RC-529 demonstrated that even though MPL can enhance primary CD4 T 
cell expansion and Th1 differentiation, long-term CD4 T cell response were better promoted 
with LPS than MPL [15]. For this reason, we used LPS as an adjuvant in our vaccine model. 
Furthermore, the addition of costimulation, also increases the effectiveness of T cell priming. 
For example, OX40 (CD134) costimulation supplied in the form of agonist antibody (anti-
CD134) enhances CD4 T cell clonal expansion, survival, and memory [16-18]. Importantly, 
LPS can synergize with anti-CD134 to further enhance the CD4 T cell expansion and survival 
[19]. A fundamental understanding of how LPS and CD134 agonist induced responses 
promote T cell survival can be beneficial in development of an optimal T cell inducing vaccine. 
With the aim of understanding LPS induced mechanisms, previous studies in our lab showed 
that, LPS induced TRIF (TIR-domain-containing adapter-inducing interferon-β)	  signaling is 
essential for promoting effector CD4 T cell accumulation to non-lymphoid tissues of liver and 
lung [20]. However, TRIF induced cytokines TNF-α, IL-10, IFN-γ did not play a role in the T cell 
accumulation. Following this, a recent study suggested that lipid A-TRIF induced type 1 IFN 
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signaling (IFNαR signaling) is important for Ag-specific CD4 T cell expansion. We therefore, 
hypothesized that LPS induced type I IFN could play a dominant role in promoting the synergy 
between, LPS and CD134 agonist. Thus, in the 1st chapter of thesis we will focus on 
understanding the role of LPS induced IFNαR signaling in promoting Ag-specific CD4 T cell 
response in the vaccine model combining Ag with LPS and CD134 agonist.  
Another adjuvant, poly I:C, a synthetic analog of viral dsRNA, has been studied in vaccines 
developed against infectious diseases such as HIV, malaria, HPV as well as in certain cancers 
[21-26]. Poly I:C was shown to be a superior adjuvant to MPL in the induction of CD4 Th1-type 
response to dendritic cell–targeted HIV gag protein vaccine [21]. Importantly, poly I:C induced 
CD4 T cell immunity depended on IFNαR signaling [22]. Furthermore, the combination of poly 
I:C and CD40 agonist that promotes synergistic CD4 T cell expansion and Th1 differentiation 
requires functional IFNαR signaling in DC’s [27]. Authors in this study showed that IFNαR 
signaling induced CD134L expression on CD8+ DC’s is essential for the synergistic effect of 
poly I:C and anti-CD40. Therefore, we hypothesized that combining poly I:C directly with 
CD134 costimulation could promote enhanced CD4 T cell response. Thus, in the 4th chapter of 
thesis, we will present the study of combined administration of Ag, poly I:C and anti-CD134 
mAb and its effect on specific-CD4 T cell expansion and Th1 differentiation. Knowledge gained 
from this study could be useful in optimal development of vaccines against diseases such as 
HIV, HPV, malaria and certain forms of cancer where poly I:C is already been shown to be a 
promising adjuvant.  
 
A. LPS as an adjuvant 
TLR4 recognizes pathogen associated bacterial LPS, the primary cell wall component of the 
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outer membrane of gram-negative bacteria [28]. Bacterial LPS consists of a hydrophobic lipid 
A, a hydrophilic core polysaccharide chain and O-antigen repeating units [29]. The lipid A 
portion of the molecule is responsible for exerting the bacteria’s endotoxic effects. Initial 
studies showed that Lipid A stimulates macrophages via TLR4 resulting in the secretion of 
proinflammatory cytokines leading to the pathogenesis of septic shock [30, 31]. However, the 
ability of LPS to induce several cytokines, induce APC maturation and directly promote CD4 T 
cell survival, established it as a valuable vaccine adjuvant [3, 11]. Since then a large body of 
research has been devoted towards investigating the adjuvant effects of LPS on lymphocytes. 
 
1. LPS Detection  
LPS recognition by innate receptors involves the association of LPS binding protein (LBP) with 
LPS molecules followed by its transfer to CD14 receptor [28]. CD14 lacks a transmembrane 
domain and does not signal in the presence of LPS. Rather, CD14 directs LPS to TLR4, which 
initiates the signaling process. Another important molecule is myeloid differentiation factor 2 
(MD-2), which is associated with TLR4 on the cell surface [32]. MD-2 directly binds LPS, 
thereby conferring TLR4 responsiveness. B cells also express the receptors RP105 and MD-1, 
structurally related to TLR4 and MD-2, which are important for their LPS response [33]. 
 
2. LPS induced TLR4 Signaling  
The intracellular portion of TLR4 contains a Toll/interleukin-1 receptor (TIR) domain that is 
common to all members of the TLR family [34]. This TIR domain recruits cytoplasmic adaptors, 
named myeloid differentiation primary response protein 88 (MyD88), TIR domain-containing 
adaptor protein/MyD88-adaptor-like (TIRAP/Mal), TIR domain-containing adaptor inducing 
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IFN-β/TIR-domain-containing molecule 1 (TRIF/TICAM 1) and TRIF-related adaptor 
molecule/TIR-domain-containing molecule 2 (TRAM/TICAM 2). TIRAP recruits MyD88 [35, 36], 
while TRAM recruits TRIF to TLR4 [37], resulting in two distinct signaling pathways (see 
Figure. 1-1). Upon sensing LPS, TIRAP is thought to interact with TLR4 at PI(4,5)P2-rich 
plasma membrane subdomains and recruit cytosolic MyD88, which eventually leads to the 
assembly of myddosome, a protein complex consisting of TIRAP, MyD88, and IRAK family 
kinases. This complex promotes proinflammatory cytokine production. The MyD88 pathway 
begins with the phosphorylation of IL-1 receptor associated kinases (IRAK), IRAK4 and IRAK1, 
leading to activation of TNF receptor-associated factor 6 (TRAF6). TRAF6 activates 
transforming growth factor-β-activated protein kinase 1 (TAK1). TAK1 then activates IKK 
complex and MAP kinase pathway, leading to degradation of IkB and activation of C-Jun N-
terminal kinase (JNK) and p38. LPS also activates extracellular signal-regulated kinase (ERK) 
through MEK1 and MEK2. MyD88-dependent signaling ultimately results in the activation of 
NF-kB and AP-1 transcription factors [28, 38].  
TLR4 could be internalized into endosomes where it engages TRAM, to recruit TRIF [39]. 
Importantly, the plasma membrane signaling of TLR4 could be uncoupled from its endosomal 
signaling. The TRIF pathway begins with the recruitment of receptor interacting protein 1 
(RIP1) and TRAF6, both of which cooperate to activate NF-kB. In addition, TRIF activates 
TANK-binding kinase 1 (TBK1) and IKKi, resulting in the phosphorylation of interferon 
regulatory factor 3 (IRF3) [38, 40]. Initial IFN-β production is IRF3-mediated and IFN-β 
amplifies type I IFN production further through induction of IRF7. IRF3 and IRF7, along with 
NF-kB and ATF2/c-Jun, induce the transcription of IFN-β. Thus, MyD88 and TRIF signaling 
pathways fully account for the adjuvant activity of LPS [40, 41]. 
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3. Role of the adjuvant LPS in CD4 T cell activation and effector differentiation. 
Considering the central roles of CD4 T cells in assisting both B cell and CD8 T cell responses, 
the effects of LPS on CD4 T cells is of considerable interest. By tracking Ag-stimulated T cells 
in vivo our understanding of LPS adjuvanticity has greatly increased. The superantigen model 
is best suited for studying endogenous CD4 T cell responses, where Staphylococcal 
Enterotoxin A (SEA) binds and activates Vβ3 receptor expressing T cells by linking them with 
MHC class II molecules on APCs [42]. Injecting SEA from staphylococcus aureus into mice 
results in significant expansion of Vβ3 T cells followed by their contraction over the next few 
days [43]. Importantly, injecting LPS 24 hours after SEA, rescues Vβ3 T cells from dying and 
results in about five-fold increase in their numbers [10]. Subsequent reports demonstrated that 
LPS can also increase the accumulation of peptide-stimulated CD4 T cells [44, 45]. The ability 
of LPS to enhance T cell survival was attributed to MyD88 dependent induction of 
inflammatory cytokines such TNF and IL-1 [46]. However, injecting TNF or IL-1 along with Ag 
does not result in T cell survival, to the same level as LPS, suggesting involvement of other 
factors for full adjuvant effect of LPS [44]. In line with this observation, CD11c+ cells were 
shown to be important for production of IFN-γ by T cells and their Th1 differentiation [11]. In an 
attempt to examine other MyD88-independent factors that contribute to LPS induced effector 
differentiation of CD4 T cells, TRIF signaling was shown to be important for accumulation of 
Ag-specific CD4 T cells to non-lymphoid tissues of liver and lung and their Th1 differentiation 
[20]. A similar study, using Lipid A instead of LPS, suggested that TRIF mediates its adjuvant 
effect on T cells through induction of type I IFN [47]. It is known that type I IFN can enhance T 
cell response by either directly acting on CD4 T cells and enhancing their survival [48, 49] or 
indirectly by inducing expression of costimulatory molecules on APC’s [50-52]. Therefore, we 
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hypothesized that LPS induced IFNαR signaling can promote Ag-specific CD4 T cell 
expansion and or accumulation in our vaccine model, which could explain how LPS and anti-
CD134 synergize to enhance the CD4 T cell expansion and survival. 
 
B. Role of the adjuvant poly I:C in T cell response 
Many laboratories use synthetic dsRNA to study the immune response against dsRNA viruses 
or once that generate dsRNA intermediates during viral replication. One such example is poly 
I:C, a nucleic acid duplex consisting 1 strand of polyriboinosinic acid and a complementary 
strand of polyribocytidylic acid. Poly I:C can activate both Toll like receptor 3 (TLR3) and 
melanoma differentiation associated gene 5 (MDA5) signaling pathways [53-57]. Activation of 
both TLR3 and MDA5 optimizes the magnitude and durability of CD4 Th1-type immunity as 
well as CD8 T cell immunity compared to either pathway alone. This highlights a central 
feature of potency of poly I:C as compared to other TLR adjuvants. Below I will explain, how 
poly I:C and its derivatives are used as adjuvants to promote T cell response in several 
infectious diseases and cancer.  
 
1. Poly I:C and its derivatives as vaccine adjuvants 
Poly I:C as an adjuvant 
Poly I:C’s role as an adjuvant has been tested in several experimental vaccine models. Two 
recent studies demonstrated that poly I:C induces durable and protective CD4 T cell immunity 
when used as an adjuvant in vaccines that targets DEC-205 DCs [21, 22]. In these settings, 
poly I:C boosted DC activation and CD4 T cell response by promoting the systemic release of 
type I IFN from both non-hematopoetic (stromal) and hematopoietic cells (macrophages and 
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DCs). Inclusion of poly I:C in an HIV vaccine consisting of purified recombinant gp120 antigen 
has shown to promote the generation of MHC class I-restricted CD8 T cells in vivo [58]. 
Whereas a study testing poly I:C as a mucosal adjuvant, showed that intranasal administration 
of poly I:C, induces enhanced levels of CXCL10 in the airways, correlating with the increased 
migration of CXCR3+ CD4 and CD8 T cells [59]. This suggests the potential use of poly I:C as 
an adjuvant in vaccines against mucosal infections. In the quest for vaccines against cancer, 
poly I:C has been shown to enhance tumor specific T cell responses [60]. However pre-clinical 
studies in primates showed that poly I:C is easily degraded by serum nucleases, with 
subsequent reduction in type I IFN secretion and anti-tumor activity [61]. Increasing the dosage 
of poly I:C has not been successful, as its not well-tolerated. Thus, several derivatives of poly 
I:C have been synthetized and tested for their safety and adjuvanticity, such as poly I:CLC and 
poly I:C12U. 
 
Poly I:C12U as a vaccine adjuvant 
Poly I:C12U (Ampligen®) is a modified version of poly I:C, with mismatched uracil and 
guanosine residues [62]. The mismatch in the molecule’s backbone results in its reduced 
toxicity and decreased half-life in vivo. Poly I:C12U signals exclusively through TLR3 but not 
through MDA-5. Intranasal administration of poly I:C12U with hemagglutinin (HA)-based H5N1 
influenza vaccine, has shown to enhance the levels of protective, specific mucosal IgA and 
systemic IgG responses than the adjuvant-free vaccine [63]. In phase II and III clinical trials for 
HIV vaccines, and in phase I and II cancer vaccine studies, poly I:C12U was shown to induce 
maturation of myeloid DCs, secretion of IL-12, inhibition of IL-10, and enhanced Ag-specific 
CTL and Th1-type CD4 T cell responses [64, 65]. In both cases, poly I:C12U has been deemed 
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safe for use. In 2009, a study was conducted to compare the efficacy, between poly I:C12U and 
poly I:CLC as adjuvants in a protein based vaccine utilizing keyhole limpet hemocyanin (KLH) 
as an Ag [66]. Both, poly I:C12U and of poly I:CLC potentiated CD4 T-cell proliferation; 
however, three-times as much poly I:C12U by mass was required to obtain the same Ag-
specific CD4 T-cell proliferation in the host (rhesus macaques) as with poly I:CLC, suggesting 
that poly I:CLC can be utilized in less quantity to obtain protective CD4 T cell immunity.  
 
Poly-ICLC as a vaccine adjuvant 
Poly I:CLC (Hiltonol®), is a synthetic derivative of poly I:C stabilized with poly-L-lysine in 
carboxymethyl cellulose to make it less sensitive to serum-degradation [67]. The ability of poly 
I:CLC to elicit a strong Th1 response makes it a very attractive adjuvant [21, 68]. In RTS,S 
vaccine for malaria developed against plasmodium falciparum infection, it was shown that mice 
immunized with poly I:CLC + RTS,S induced significantly higher Th1 CD4 T-cell responses 
than mice vaccinated with RTS,S + GLA/SE (glucopyranosyl lipid adjuvant-stable emulsion), 
and poly I:CLC + RTS,S combination provided approximately 50% protection [23]. Moreover, 
the poly I:CLC + RTS,S combination was also immunogenic in non-human primates resulting 
in production of Ag-specific, polyfunctional CD4 T cells and antibody production [69]. In an HIV 
vaccine study, inclusion of poly I:CLC in a gag recombinant protein vaccine where gag p24 
was fused to DEC-205 resulted in polyfunctional CD4 and CD8 T-cell responses in rhesus 
macaques [70]. Additionally, in phase I ovarian cancer trial, patients treated with NY Eso 
peptides + poly:ICLC formulated with Montanide-ISA-51 showed enhanced peptide-specific 
antibody, CD8 and CD4 T cell responses [71].  Currently several ongoing Phase I and II 
clinical trials of studying intratumoral administration of poly:ICLC in patients with liver cancer, 
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pancreatic cancer, melanoma, sarcoma, and head and neck cancer have demonstrated the 
safety of this approach, but efficacy data are not yet available.  
 
2. Poly:IC detection 
Toll-like Receptor 3 (TLR3) 
TLR3 was the first identified as a dsRNA receptor while studying poly I:C responsiveness in 
the NFkB reporter cell line transfected with different TLRs [53]. In humans, TLR3 is expressed 
both on surface and intracellularly in non-immune cells such as fibroblast and epithelial cells or 
intracellularly in monocyte derived immature DCs and CD11c+ DCs [54, 72-74]. Whereas, in 
mice, TLR3 is expressed intracellularly in CD8+ DC’s and macrophages [53, 75]. Whether its 
expressed on the surface or intracellulary, TLR3 signaling, occurs intracellulary as it requires 
endosomal maturation [73]. The intracellular location of TLR3 poses a challenge to ligand 
recognition. A recent study demonstrated that CD14 enhances dsRNA-mediated TLR3 
activation by directly binding to poly I:C and mediating its cellular uptake [74]. The internalized 
poly I:C colocalizes with CD14 and TLR3. As extracellular domain of CD14 consists of leucine 
rich repeat (LRR) [76], poly I:C might be transferred from CD14 to TLR3. 
 
TRIF-signaling pathway  
Among all the members of the TLR family, TLR3 is the only one that uses TRIF but not the 
MyD88 signaling pathway [77, 78]. Upon ligand-binding, TRIF is recruited to the cytosolic TIR 
domain of TLR3, similar to TLR4-TRIF (see Figure. 1-2). TRIF recruits RIP1 and TBK1 
downstream. RIP1 is phosphorylated and polyubiquitinated by the E3 ubiquitin ligase, Peli1. 
Polyubiquitinated RIP1 forms a complex with TRAF6 and TAK1. TRAF6 is an ubiquitin ligase 
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whose substrates include TRAF6 itself and NF-κB essential modifier (NEMO). Ubiquitinated 
TRAF6 and NEMO recruit and activate TAK1. Additionally, TAK1 is part of a protein kinase 
complex that further activates two pathways [79]. On one end, TAK1 phosphorylates and 
activates MAPK, to phosphorylate AP-1. AP-1 dimerizes and enters the nucleus, contributing 
to the transcription of cytokine genes. On the other end, TAK1 activates the NEMO-IKKα-IKKβ 
complex. This protein complex phosphorylates IkB, targeting it for proteosomal degradation 
and releasing NFkB (p50/RelA dimer) that enters the nucleus and induces cytokine gene 
transcription.  
TRIF mediated IFN-β induction requires activation of TBK1 kinase. This activation step is 
achieved through recruitment of TRAF3. TRIF associates with TRAF3, NAK-associated protein 
1 (NAP1), TANK-binding kinase 1 (TBK1) and IKK-i (IκB kinase-i). Activated TBK1 and IKK-i 
phosphorylates IRF3 that dimerizes and enters the nucleus to initiate IFN-β gene transcription 
[80, 81]. Transcriptional activation of pro-inflammatory cytokine genes requires the binding of 
NFkB and AP-1 dimer to the promoter region, whereas transcription of type I IFN genes is 
more stringent, requiring the combined activities of IRF3, NFkB and AP1 [77]. Additionally, 
phosphoinositide 3-kinase (PI3K) is required for the full activation of IRF3 and NFκB [82].  
 
RNA helicases MDA5, RIG-I and LGP2  
Unlike TLR3, whose expression is more restrictive, RNA helicases RIG-I, MDA5 and LGP2 are 
expressed ubiquitously [84-86,171]. Long chain poly I:C (> 2kb) can bind both TLR3 and 
MDA5, however, RIG-I recognizes relatively short dsRNA (up to 1kb) with 5′ triphosphate [87, 
88]. Thus, if poly I:C was to be shortened by RNaselll to less than 1kbp, then it can bind RIG-I 
[89]. The protein structures of these receptors contain two important domains that are essential 
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for their function: the caspase recruitment domain (CARD) and the DExD/H box RNA helicase 
domain, with the exception of LGP2, which does not have a CARD domain. The DExD/H 
domain situated at the N terminal is the ligand-interacting domain and essential for unwinding 
the RNA substrate that is powered by ATP hydrolysis. The CARD motif is responsible for 
mediating downstream signaling. LGP2 does not have the CARD motif [84] and hence fails to 
signal [90]. Similar to RIG-I, LGP2 interacts with both ssRNA and dsRNA [91], but does not 
induce type I IFN response or NFkB transcription factor [90]; hence, it was thought to act as a 
negative regulator of RIG-I signaling. Several models were proposed for the mechanism of 
dsRNA recognition inhibition by LGP2 [92]. However, recent studies demonstrated that LGP2 
works upstream of MDA5 and RIG-I to facilitate activation of these receptors [93]. The ATPase 
function of LGP2 is essential for this function, but the exact molecular events remain unknown. 
 
RIGI/MDA5 signaling pathway 
MDA5 and RIG-I helicases recognize different RNA substrates but their downstream signaling 
pathways are similar since they both act through IFN-β promoter stimulator 1 (IPS-1) (also 
known as MAVS), a mitochondrial outer membrane-associated protein [94, 95]. In addition to 
ligand sensing, RIG-I activation requires ubiquitination by TRIM25. The interaction of RIG-I and 
MDA5 with MAVS is mediated through their CARD domain. From this point, MAVS associates 
with TRAF3 (a ubiquitin ligase) and activates TBK1 in a similar fashion to the TRIF pathway 
(Figure. 1-2). Three proteins that are functionally similar to each other, TANK, NAP1 and 
SINTBAD, are important in facilitating the type I IFN response mediated by both TRIF and 
MAVS [96].  Additionally, MAVS interacts with FADD and RIP-1 via non-CARD region to 
facilitate NF-kB activation. It was found that FADD interacts with both MAVS and caspase 8 
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and 10 and processed forms of caspase 8 and 10 are important for NFkB activation as well as 
cell apoptosis [97]. 
 
In Summary 
The studies reviewed above, strongly suggest that poly I:C or its derivatives can induce 
multifunctional CD4 and CD8 T cell responses and induce maturation of DCs. Importantly, if 
poly I:C is combined with other signaling pathways, it may result in further enhancement of the 
T cell response. Indeed, specific CD4 T cells were shown to be synergistically activated by 
administration of Ag together with poly I:C and a CD40 agonist. This synergistic effect was 
dependent on expression of IFNαR and CD134L on DC’s. Thus, in 4th chapter of thesis we will 
study if poly I:C can be combined directly with CD134 costimulation to generate enhanced 
CD4 T cell expansion and Th1 subtype differentiation. If poly I:C and anti-CD134 synergize to 
promote enhanced CD4 Th1 type cell response, this combination could be used to develop an 
effective Th1 response inducing vaccine. 
As this thesis focuses on studying how LPS and poly I:C induced type I IFN impacts CD4 T cell 
response, below we will address the general characteristics of type I IFN and what’s known 
about its role in enhancing CD4 T cell immunity. 
 
(II). Type I IFN Interferon 
A. Role of Type I Interferon 
Type I IFNs were first identified more than 50 years ago as an “inhibitory factor” of viral 
replication [98]. They belong to a family of closely related cytokines and consist of the products 
of numerous IFN-α genes, a single IFN-β gene (in mice and humans) and several other genes 
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that are expressed variably in different species (IFN ω, −τ, −κ ,  −ε, −δ and limitin) [99]. Type I 
IFN can be produced by all nucleated cells and although all type I IFN members signal through 
the same receptor complex [100, 101], their signaling can result in diverse effects depending 
on the engaged type I IFN, the responding cell and timing of the signaling (before or after T cell 
receptor (TCR) activation)) [102, 103]. The anti-viral effects of type I IFN are ascribed to the 
induction of interferon stimulated genes (ISGs) that result in production of proteins such as, 2ʹ-
5ʹ oligoadenylate synthases (OAS), dsRNA-dependent protein kinase (PKR) and Mx. [104-
106]. 2ʹ-5ʹ OAS catalyzes the formation, of 2ʹ-5ʹ oligoadenylates to activate the ribonuclease 
RNase L that degrades the viral and cellular RNA. Whereas PKR, is a serine/threonine kinase 
that binds dsRNA and phosphorylates eukaryotic translation initiation factor alpha subunit 
(elF2a) to block viral RNA translation. The Mx protein family are large GTPases that complex 
with dynamin to disrupt the trafficking or activity of viral polymerase and thereby interfere with 
viral replication. The importance of type I IFNs in viral infections has been demonstrated in 
mouse models, where infection of mice lacking the IFNαR1 fail to control viral replication of 
vesicular stomatitis virus (VSV), semliki forest virus (SFV), vaccinia virus (VV) and lymphocytic 
choriomeningitis virus (LCMV) [107].  
Apart from induction of the anti-viral protein, type I IFN receptor (IFNαR) signaling also 
activates other immune cells, including phagocytes [108-110], NK cells [111, 112] and T cells 
[48, 113]. Type I IFNs can act directly on T cells and NK cells, leading to their activation and 
acquisition of effector functions for elimination of the pathogen. Additionally, type I IFNs can 
act on APCs to promote their full activation and maturation [114, 115].  
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B. Type I IFN Signaling 
All type I IFN family members signal through the complex, consisting of IFNαR1 and IFNαR2 
subunits [101] (See, Figure. 1-3). Binding of type I IFN leads to the dimerization of these two 
subunits bringing Janus kinase 1 (Jak1) associated with IFNαR2 into close proximity with the 
tyrosine kinase 2 (Tyk2) [116, 117]. This leads phosphorylation and activation of Tyk2, which 
then cross phosphorylates Jak1. Jak1 then phosphorylates IFNαR1, providing a docking site 
for signal transducer and activator of transcription (STAT) proteins. Binding of STAT leads to 
their phosphorylation, dissociation from the receptor complex and translocation to the nucleus 
leading to regulation of IFN induced genes [101]. The major transcription factor formed in 
response to type I IFN is interferon-stimulated gene factor 3 (ISGF3), a heterodimer of STAT1 
and STAT2 combined with IFN-regulatory factor 9 (IRF9) [118]. ISGF3 binds to interferon 
regulated response elements (ISREs), contained in the promoters of ISGs. Although STAT1 
and STAT2 are the most important mediators, IFNαR can also activate STAT1 and STAT3 
homodimers and heterodimers in most cell types and activate STAT4, STAT5 and STAT6 in 
certain cell types [119]. Interestingly, different STATs have different biological effects. IFNα/β 
provides pro-survival and mitogenic signals, possibly through STAT3 and STAT5, rather than 
antiproliferative signals through STAT1 [120], [121]. On the other hand, type I IFN induced 
STAT4 is required for IFN-γ production from CD8 T cells during lymphocytic choriomeningitis 
virus (LCMV) infection, whereas, STAT1 negatively regulates IFN-γ production [122, 123]. The 
relative abundance of these STATs, which may vary depending on cell type and activation 
state is likely to have a major impact on the overall response to type I IFN.  
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C. Role of Type I IFN signaling in adaptive immune response 
1. Influence of type I IFN signaling on DC’s 
Several studies in both human and mouse systems suggest that type I IFN can influence the 
adaptive immune cell response by acting on DCs. Type I IFN act on immature DCs to enhance 
their cell-surface expression of MHC and co-stimulatory molecules (CD80 and CD86) 
endowing them with a better ability to stimulate T cells [51, 52, 124]. Type I IFN also promotes 
the ability of DCs to cross present Ags to CD8 T cells during viral infections, such as vaccinia 
virus and LCMV infections [115, 125]. Additionally, type I IFN may promote migration of DCs to 
lymph nodes, by up regulating their chemokine receptor expression, to help prime and activate 
T cells [126, 127]. DCs are potent producers of IL-12, which is important for driving Th1 
differentiation and IFN-γ production by T cells. In some settings, IFNαR signaling has been 
shown to induce IL-12 from DCs following PRR stimulation [128]. However, high but 
physiological levels of type I IFN can also inhibit IL-12 production during MCMV and LCMV 
infections [129, 130]. This mechanism may have developed to favor optimal cytotoxic 
responses by T cells and NK cells in response to virus, while limiting the pathological effects of 
excessive IL-12 production [131]. Overall, type I IFN can influence T cell response by inducing 
DC maturation, their expression of costimulatory or chemokine receptors, and secretion of 
cytokines such as IL-12. 
 
2. Influence of type I IFN signaling on T cells  
The role of type I IFN in modulating T cell responses first became evident from studies 
investigating the effects of injecting type I IFN, together with Ag’s in experimental models. 
Timing of type I IFN exposure is important in deciding the fate of T cell response, where pre-
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exposure to type I IFN was found to inhibit, whereas type I IFN given at same time and/or after 
antigen was shown to augment CD4 and CD8 T cell response [132].  
 
Role of type I IFN in T cell survival 
Definitive evidence that T cells were direct cellular targets of type I IFN came from studies with 
adoptive transfer of transgenic T cells lacking IFNα/βR receptor against different MHC class I- 
or II-restricted peptides of LCMV virus into IFNα/βR+/+ mice. This resulted in dramatic reduction 
of specific CD4 and CD8 T cell expansion and generation of memory as compared to transfer 
of IFNα/βR+ control T cells [133-135]. The reduced accumulation of T cells was due to poor 
survival of activated T cells rather than their inability to proliferate. Moreover, reduced 
accumulation of IFNαR1−/− CD8+ T cells was associated with lower expression of the anti-
apoptotic proteins Bcl-xL and Bcl-2 [136]. Direct evidence that type I IFN can prevent the death 
of activated CD4+ and CD8+ T cells in vitro has been reported for mouse [48] and human T 
cells [49]. In these studies, activated T cells exhibited a lower rate of death when cultured in 
the presence of type I IFN than when placed in medium alone. 
In contrast to the evidence that type I IFN can enhance the survival of activated T cells, it has 
also been reported to increase T cell death under certain conditions. For instance, this has 
been shown in an in vitro model of activation induced cell death (AICD), in which pre-activated 
human T cells were exposed to anti-CD3, triggering a certain degree of apoptosis. Here, 
addition of IFN-α with anti-CD3 induces a greater proportion of apoptotic T cells than anti-CD3 
alone [137]. In this case, the pro-death effects of type I IFN could be a feedback mechanism to 
prevent T cell-mediated pathology such as that seen during chronic infection, where high 
levels of viral Ags and type I IFN persist beyond the acute stage of infection. Consistent with 
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this, injection of IFN-α into mice relatively late during an immune response (day 8) has shown 
to augment expression of programmed cell death-1 (PD-1), a negative regulator of TCR 
signaling [138].  
 
Role of type I IFN in T cell proliferation 
Like T cell survival, the effect of type I IFN on cell proliferation also depends on timing and 
context of signaling. It has been shown that pre-exposure to type I IFN significantly inhibits the 
proliferation of both purified mouse [139] and human T cells [140]. Further evidence of this 
came from a study, where human T cells that were pretreated with IFN-α for 18–20 h before 
anti-CD3/CD28 mediated stimulation showed reduced proliferation, however addition of IFN-α 
to activated T cells did not inhibit the proliferation [141]. This outcome was associated with 
enhanced expression of IL-2Rα as well as genes associated with cell proliferation (c-myc) and 
cell survival (pim-1) after adding IFN-α to activated T cells [142], whereas T cells treated with 
IFN-α before stimulation had reduced IL-2 and IL-2R expression [140]. Additional confirmation 
that the nature of signaling through IFNαR can be altered following T-cell activation came from 
study, showing that in response to LCMV infection in mice the proliferating CD8 T cells 
downregulate STAT1 expression, which is associated with anti-proliferative activity of type I 
IFN [143].  
These findings suggest that the timing of exposure to type I IFN relative to antigen is critical in 
determining if T cell proliferative response is enhanced or suppressed.  
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Role of type I IFN in effector T cell differentiation  
Role of type I IFN in T cell differentiation came from initial studies showing that IFN-α/β	  
induces differentiation of APC-activated naive mouse T cells into CTL, increasing their cytolytic 
activity, IFN-γ expression, and perforin and granzyme B expression [144]. Similarly, type I IFN 
was shown to promote the cytolytic activity and IFN-γ secretion by CD3/CD28-stimulated 
human CD8+ T cells [145]. In comparison in vivo, work showed that type I IFN unresponsive 
mouse CD8+ T cells responding to LCMV infection were found to secrete less IFN-γ and 
degranulate less effectively than WT cells [136].  
In terms of CD4 T cells, although type I IFN on its own appears to be insufficient to serve as a 
polarizing factor for Th1 differentiation, it can act in concert with other cytokines to promote 
Th1 differentiation. For instance, IFN-α has been shown to increase the production of IFN-γ by 
anti-CD3/CD28 stimulated human CD4+ T cells in the presence of IL-12 that was associated 
with IFN-α-mediated enhancement of IL-12Rβ2 expression [146] Similarly, treatment of anti-
CD3-activated human T cells with IFN-α was shown to increase the expression of IL-18R, 
which correlated with increased production of IFN-γ in response to treatment with IL-12 + IL-18 
together [147]. IFN-α has also been shown to increase IL-21 expression when added with anti-
CD3, or when added to anti-CD3/CD28 pre-activated human T cells [148]. IL-21 can act in 
concert with IL-18 to enhance IFN-γ, suggesting another possible mechanism by which type I 
IFN could promote Th1-type responses [149]. 
While contributing positively to Th1 polarization, type I IFN has been shown to be inhibitory on 
other T cell differentiation fates. Type I IFN has been reported to inhibit the differentiation of 
human naive CD4 T cells towards a Th2 phenotype and to reduce production of Th2 cytokines 
from pre-committed Th2 cells [150]. IL-5 appears to be the Th2 cytokine most strongly affected 
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by type I IFN [151, 152]. IFN-α has been shown to regulate the response of human CD4 and 
CD8 T cells to IL-4 in a complex manner, enhancing IL-4R mediated signaling at early time 
points (6  h), but inhibiting this response at later times (12–24  h) [153]. IFN-α has also been 
reported to inhibit the differentiation of mouse and human naive CD4 T cells in vitro (activated 
with anti-CD3/CD28 under Th17 polarizing conditions) into Th17 cells [154]. Taken together, 
these results indicate that positive effects on type I IFN on Th1 differentiation and negative 
effects on Th2 and Th17 polarization likely influences its capacity to drive type 1 responses in 
vivo.  
 
Role of type I IFN in memory T cell responses 
Finally, in addition to modifying effector T-cell differentiation, there is evidence that direct 
stimulation of T cells by type I IFN contributes to the generation of memory T cells. This was 
suggested indirectly in a study where the role of IFNαR mediated signaling in CD8 T cells was 
examined after LCMV infection [134]. Here, the numbers of both effector and memory CD8 T 
cells were greatly reduced for type I IFN unresponsive T cells compared to the control cells. 
However, given that memory T cells can arise from effector T cells, the reduction in memory 
cells may be simply a consequence of diminished initial T-cell expansion. Indeed, the 
generation of functional memory cells was confirmed from IFNαR1−/− CD8+ T cells in a similar 
LCMV infection model [155]. Here the absence of IFNαR1 in CD8 T cells resulted in reduced 
generation of short-lived effector T cell (SLEC), however, generation of memory precursor 
effector cells (MPEC) that gave rise to functional memory CD8 T cells was unaffected. By 
contrast, experiments studying the response of IFNαR1−/− CD8 T cells in a bacterial, Listeria 
monocytogenes infection model demonstrated a markedly reduced generation of memory cells 
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despite strong primary expansion [156]. A recent study showed that when human CD8 T cells 
were activated by IFN-α and IL-12 together, IL-12 programs development of effector memory 
cells (TEM) by induction of IL-12R on actively dividing cells. In contrast, IFN-α slowed the cell 
division in some cells, resulting in their acquisition of central memory (TCM) phenotype [157].  
In terms of CD4 T cells, there have been very few reports showing that type I IFN can promote 
memory CD4 T cell responses. Recently, it was shown in an in vitro study that IFN-α 
synergizes with IL-12, when added to anti-CD3/CD28 stimulated naive human CD4+ T cells, to 
produce IL-2-secreting CD4 T cells that display the characteristics of TCM cells and generate 
IFN-γ upon secondary activation [158]. These results are different than seen for human CD8 T 
cells, where IL-12 programs the development of TEM cells, whereas IFN-α results in 
development of TCM cells. However, overall type I IFN alone or in combination of cytokines 
such as IL-12 can promote the development of both CD8 and CD4 memory T cells, where 
most reports suggest that type I IFN promotes the development of central memory cells.  
 
In summary 
The overall role of type I IFN in promoting T cell responses could rely on its direct effect of T 
cells by influencing their survival, proliferation and differentiation or it could be coupled with its 
indirect effects on other cell types such as DC’s. Alternatively, it is be possible that type I IFN 
induced downstream signaling pathways influence the overall quality and magnitude of the T 
cell response, where Type I IFN signaling may enhance the expression of chemokine 
receptors on T cells to allow their accumulation to certain peripheral tissues. Several studies 
have reported that CD4 and CD8 T cells recovered from inflamed peripheral tissues in human 
autoimmune diseases were highly enriched in CXCR3 expression relative to T cells found in 
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the blood [159-161]. In addition, CXCR3 ligands were also highly expressed in these same 
diseased tissues. In fact, previous studies in our lab, showed than LPS induced TRIF signaling 
in host cells, promotes CXCR3 expression on specific-T cells. Up-regulated CXCR3 
expression might explain how TRIF mediates T cell accumulation to peripheral tissue such as 
liver. LPS used in our vaccine model can result in development of IFN-γ producing Th1 cells 
and Th1 cells are almost exclusively CXCR3 positive [162, 163]. Hence, one of our aims is to 
understand, if LPS-TRIF induced IFNαR signaling can enhance the expression of CXCR3 on 
specific-CD4 T cells to promote their migration or accumulation to peripheral tissues of liver 
and lung. Below I will review, the role of CXCR3 and it’s ligands in promoting T cell responses 
in various diseases. 
 
III. Role of CXCR3 and it’s ligands in promoting CD4 T cell response 
A. CXCR3 and its ligands 
CXCR3 is composed of 368 amino acids (aa) and is a seven-transmembrane G-protein 
coupled receptor [164]. It is mainly found in two alternatively spliced forms, CXCR3-A [165] 
and CXCR3-B [166]. Recently a third splice variant, CXCR3-alt was discovered [167]. Ligands 
for CXCR3 include the chemokines, CXCL9, CXCL10, and CXCL11, formerly known as 
monokine induced by interferon-γ (Mig), interferon-γ inducible 10-kDa protein (IP-10), and 
interferon-inducible T cell α chemoattractant (I-TAC) respectively [159, 165, 168]. Although 
both forms of CXCR3-A and CXCR3-B can bind CXCL9, CXCL10 and CXCL11, the CXCR3-A 
has a higher affinity for them and can outcompete CXCR3-B [166]. These two forms of the 
receptor operate by different signaling pathways, and thus lead to different outcomes when 
activated. It is likely that CXCR3-A binds to the CXCL9 and CXCL10 in our vaccine model, 
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however we will not be addressing which receptor specifically binds to the chemokines in our 
study. CXCR3-alt encodes a truncated version of the receptor that is 260 aa in length and is 
predicted to have four or five transmembrane domains [167]. Chemotaxis studies show that 
this change in structure abolishes CXCR3-alt’s ability to interact with CXCL9 and CXCL10, but 
retain’s its activity to interact with CXCL11. It is important to note that, C57BL/6 mice does not 
possess a functional CXCL11 gene, since a point mutation and single-base deletion in its 
leader sequence, results in a reading frame shift introducing a stop codon early within the gene 
[169, 170]. Hence we will not be addressing the role of CXCL11 in promoting T cell response. 
 
B. Chemokine induction 
It is important to note that the CXCR3 ligands are differentially induced. CXCL9 is strongly 
induced by IFN-γ, but most studies suggest that type I IFN does not directly induce CXCL9 but 
rather synergizes with cytokines such as IL-18 to produce IFN-γ which may then induce 
CXCL9 [171, 172]. Again TNF cannot alone induce, but rather synergizes with IFN-γ to induce 
CXCL9 [173]. Whereas, CXCL10 is strongly induced by IFN-γ as well as by the type I IFN and 
weakly by TNF, although TNF can synergize with type I IFN to induce CXCL10 [171, 174]. In 
our model LPS and poly:IC induced IFN-γ (produced by Th1 cells) may result in induction of 
CXCL9 and CXCL10 or type I IFN may synergize with cytokines such as IL-12, IL-18 or IL-21 
to induce IFN-γ which may then induce CXCL9. Whereas, CXCL10 can be directly induced by 
type I IFN. Several reports suggest that, CXCL9 and CXCL10 are released by stromal cells, 
macrophages, DCs, neurons or endothelial cells, depending on the kind of pathogen involved 
and site of infection [175-179]. In our study as well, these cells could contribute to production 
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of CXCL9 and CXCL10, however, we have not specifically analyzed the cells responsible for 
induction of these chemokines. 
 
C. CXCR3 signaling 
CXCR3 is a seven-transmembrane-spanning glycoprotein receptor that mediates it action 
through a G-protein coupled signaling pathway [164]. Heterotrimeric G proteins consist of Gα, 
Gβ and Gγ subunits, of which the latter two proteins are tightly bound [180]. The Gα subunit 
harbors a GTP hydrolase catalytic site that is occupied by GDP when the G protein is in the 
inactive state. On binding of a G protein to an activated receptor, GDP dissociates from the G 
protein and is replaced by GTP. Subsequently, the G protein dissociates from the receptor and 
the Gα-GTP and Gβγ complexes may each go on to initiate signal transduction cascades [180, 
181]. Gβγ activates the membrane-associated enzyme phospholipase Cβ2 (PLC2) [182] which 
in turn cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) to form the intracellular second 
messages phosphatidylinositol 1,4,5-triphosphate (IP3) and diacyl-glycerol (DAG). IP3 
mobilizes calcium from intracellular stores, whereas DAG acts in conjunction with calcium to 
activate various isoforms of protein kinase C (PKC). The activation of PKC and of various 
calcium-sensitive protein kinases catalyze protein phosphorylation, which activates a series of 
signaling events that eventually lead to cell movement and other responses [183-185].  
 
D. Role of CXCR3 in inflammatory diseases 
Expression of CXCR3 on activated T cells grants them entry into sites otherwise restricted. 
This has been particularly shown for infections in the brain. CXCR3 is required on CD8 T cells 
to be recruited into brain during Plasmodium berghei ANKA infection for the development of 
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cerebral malaria symptoms and CXCR3−/− mice are protected from cerebral malaria [175, 186]. 
This protection is mediated by CXCL9 and CXCL10, as mice deficient in either of these ligands 
showed partial disease protection [175]. In other models of brain inflammation, CXCL10 
appeared to have a dominant role in the recruitment of T cells into the brain. In West Nile virus 
(WNV) infection, CXCL10 expressed by neurons, induced the migration of CD8 T cells into the 
brain [187]. Moreover CD8 T cell infiltration into vaginal mucosa in Herpes Simplex Virus-2 
(HSV-2) infection for protection against the disease required CXCR3 expression [188, 189]. 
Additionally, CXCR3 expressing cells were first characterized in autoimmune rheumatoid 
arthritis synovium of human patients [160] and subsequently in murine models [190, 191]. 
CXCR3 mediated T cell infiltration is also known to play a role in development of autoimmune 
insulitis diabetes [192] and systemic lupus erythematosus (SLE) [193]. 
 
E. Role of CXCL9 and CXCL10 in diseases 
Dominance of CXCL9 versus CXCL10 in diseases 
In some inflammatory models, the requirement of one CXCR3 ligand dominates over other and 
its deficiency cannot be compensated by the presence of the other ligands. For example, some 
infections in the brain show importance of CXCL10 ligand over others. In dengue virus 
infection, CXCR3 and CXCL10 are more important for trafficking of CD8 effector T cells into 
the brain to provide protection [194]. Similarly, as mentioned previously, in WNV infection, 
CXCL10 expressed by neurons directs the migration of CD8 T cells into the brain [187]. 
Similarly in a model that uses acute LCMV infection of transgenic mice that expresses LCMV 
glycoprotein in the cells of the islets of Langerhans, both CXCL9 and CXCL10 were up 
regulated, but CXCL10 was expressed throughout the infiltrated islet whereas CXCL9 
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expression was limited [192, 195]. Mice treated with CXCL10 neutralizing antibodies showed 
delayed onset of insulitis, whereas CXCL9 neutralizing antibodies had no affect on disease 
progression.  
In some autoimmune diseases however CXCL9 could play a dominant role. For example, 
CXCR3 and CXCL9-deficient, but not CXCL10-deficient, Murphy Roth Large/lpr mice were 
protected from autoimmune lupus-like inflammation of the kidney [193]. Also, during acute 
infection with toxoplasma gondii, CXCL10 was shown promote CD4 and CD8 T cell infiltration 
to several peripheral organs and control the spread of disease [196], but, during the chronic 
infection, CXCL9 was more important for recruiting T cells to brain and providing protection 
[177].  
 
Collaboration of CXCL9 and CXCL10 in diseases 
In some disease models, cooperation between CXCL9 and CXCL10 is required for full T cell 
infiltration and development of effector responses. Studies by Groom et al, recently showed 
using the model of OVA-pulsed DCs injected with LPS and poly I:C as well as with LCMV 
Armstrong infection, that CXCL9 and CXCL10 binding to CXCR3 was important for promoting 
T cell-DC interaction in dLN and their subsequent differentiation into Th1 cells [197]. As 
previously mentioned, CXCR3 expression on CD8 T cells was required for their infiltration into 
the brain during P. berghei ANKA infection for the development of cerebral malaria symptoms. 
In this study, CXCL9 and CXCL10 were equally important, mouse deficient in one of these 
ligands showed partial disease protection [175]. The cooperation between CXCR3 ligands 
appears to be due to expression of these ligands by different cell types, where endothelial cells 
predominantly produced CXCL9, whereas neurons were the main source of CXCL10. 
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Similarly, in a mouse model of herpes simplex virus-2 infection, expression of both CXCL9 and 
CXCL10 were necessary for optimal recruitment of NK cells and CTLs into the spinal cord and 
control of the infection [189]. Moreover, both CXCL9 and CXCL10 were shown to provide the 
chemotactic signals for recruitment of CXCR3+ central memory CD8 T cells and their 
localization in the periphery of dLN to mount effective anti-viral responses using during LCMV 
infection [198]. 
Tissue specific expression of CXCL9 and CXCL10, has been shown to orchestrate the 
movement of CXCR3+ T cells from the lymphoid compartment to the peripheral tissue in a 
murine model of granulomatous liver disease induced by Propionibacterium acnes [199]. In 
this model, LN DCs produced CXCL10, whereas hepatic granuloma cells including the kupffer 
cells in liver parenchyma produced CXCL9. It was suggested that CXCL10 instructs CD4+ Th1 
cells to stay in the LN interacting with DCs, whereas CXCL9 expression in the periphery drives 
the recruitment of these cells out of the LN and into the liver.   
 
In conclusion 
Overall, the role of chemokines in promoting T cell recruitment could be dependent on several 
factors, such as their preferential expression in certain tissues, the type of infection, the cell 
types that produce them and availability of cytokines such as type I IFN and IFN-γ that could 
be secreted by T cells, NK cells, macrophages, stromal cells or several others following 
encounter with the pathogen. 
Having looked at how chemokine receptor or chemokines induced by the adjuvants, LPS, poly 
I:C or type I IFN impact T cell recruitment or accumulation to different tissues, will next review 
how combining, the adjuvants LPS and poly I:C with costimulatory pathways such as OX40 
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can be beneficial in promoting T cell expansion and survival. 
 
IV. Combining TLR signals with OX40 signaling  
Combined administration of Ag, LPS and costimulatory signals, has been shown previously to 
enhance CD4 T survival than Ag and LPS alone. Studies using SEA model showed that, CD40 
costimulation, which primarily acts on APCs could further enhance the T cell survival induced 
by SEA and LPS [200]. Similarly using SEA as well as the DO11.10 adoptive transfer model, it 
was shown that combination of LPS with OX40 agonist mAb that primarily acts on T cells, also 
resulted in a massive synergistic effect on T cell expansion and survival of long-term memory 
T cells [19]. However, combining LPS with both anti-OX40 and anti-CD40 did not further 
increase T cell survival, suggesting that they may work through similar or redundant 
mechanisms [200].  
Moreover, the combination of poly I:C and CD40 agonist has also been shown to enhance 
generation of effector CD4 T cells in several DEC-205 targeted vaccine models [201-203]. 
Furthermore, combining a dominant epitope of RSV with poly I:C and anti-CD40 enhanced the 
generation of RSV-specific effector memory CD8 T cells in lung airways, protecting the mice 
against infection [204]. Similarly, administration of poly I:CLC and CD40 agonist together with 
HIV envelop glycoprotein peptides in a NHP model of rhesus macaques resulted in enhanced 
generation of effector CD4 and CD8 T cells against different HIV envelop peptides in the BAL 
fluid and lung [205]. Subsequent studies addressing the mechanism of synergy between poly 
I:C and CD40, suggested that poly I:C and CD40 induced Ag-specific CD4 and CD8 T cell 
responses were dependent on OX40L and IFNαR signaling in DC’s [206]. Importantly, 
enforced OX40 costimulation was able to rescue the reduced CD4 T cell expansion in IFNαR-/- 
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mice to WT levels in poly I:C and CD40 immunization model [27], suggesting that CD40 
costimulation may work by enhancing OX40L expression and subsequent OX40 (CD134) 
signaling in T cells. Hence in the 4th chapter of the thesis we will study, if combining Ag 
together with poly I:C and anti-CD134 promotes enhanced Ag-specific CD4 T cell expansion 
and Th1 differentiation, similar to poly I:C and CD40 combination. If this combination generates 
enhanced CD4 T cell response than poly I:C and anti-CD134 alone, it could be further tested in 
vaccines against HIV, malaria, HPV and certain cancers where poly I:C or its derivatives have 
shown to provide protection in mouse or non-human primate models by promoting enhanced T 
cell responses. 
Before I address, how LPS and poly I:C induced signaling pathways impact CD4 T cell 
response, I will review what’s known about OX40 costimulation and why using it together with 
the adjuvants LPS and poly I:C could be beneficial in promoting optimal CD4 T cell immunity. 
 
V. OX40 costimulation 
A. OX40 and OX40L 
The OX40 costimulatory molecule (also called as CD134) is a member of the TNF receptor 
superfamily [17, 207, 208]. OX40 signaling has been suggested to sustain the signaling 
pathways induced by TCR, CD28, and IL-2R [17, 209, 210].  Following Ag stimulation OX40 is 
transiently induced on activated naive CD4 and CD8 T cells [207, 211]. Although TCR signals 
are sufficient for inducing OX40 expression, CD28-B7.1/2 interactions augment and sustain its 
expression [212, 213]. T cell and APC-derived cytokines like IL-1, IL-2, and TNF may further 
modulate the extent and length of expression. OX40 is not constitutively expressed, but it’s 
induced after TCR stimulation, and its expression peaks around 2-5 days after activation [17, 
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211, 214]. OX40 was originally characterized as a T cell activation marker, with preferential 
expression on CD4 T cells [207, 214, 215]. However under strong antigenic stimulation, OX40 
can also be expressed on CD8 T cells [216, 217] and gut CD8+ intraepithelial cells [218].  
OX40 ligand (OX40L) was originally identified on human T cell leukemia virus type 1 (HTLV-1) 
transformed T cells [219, 220]. OX40L is expressed on activated APCs, Ag and/or CD40 
activated B cells and CD40L activated DCs and macrophages [208, 221-223]. In some cases, 
OX40L is expressed on NK cells [224], mast cells [225] and vascular endothelial cells [226, 
227]. 
 
B. Role of OX40 in T cell expansion, survival, and memory  
A direct role of OX40 signaling in promoting T response was demonstrated in OX40 deficient 
CD4 T cells, where the initial proliferation and cytokine production was normal, however they 
were unable to maintain the response after 3-5 days and showed a defect in long-term survival 
and maintenance of effector function [17, 212, 228, 229]. Furthermore, OX40 deficiency results 
in fewer memory T cells, suggesting that it either promotes survival of effector cells that enter 
the memory pool or induce effector cells to differentiate into memory T cells [230]. Studies, 
evaluating the role of OX40 signaling in T cell survival stem from the initial observation that 
OX40 costimulation allowed T cells to proliferate and survive in vitro [209]. Subsequent studies 
employed superantigen model to study the role of OX40 signaling, since the expansion and 
contraction phase of Ag-specific T cells is well characterized in this model [43]. Administration 
of agonist anti-OX40 after sAg injection resulted in approximately 10-fold increase in CD4 T 
cells surviving the contraction phase [19]. The increased survival was accentuated by the 
addition of a danger-signal, LPS, where combination of a LPS and anti-OX40 led to a 60-fold 
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increase in the generation of Ag-specific memory T cells. In another study using adoptive 
transfer of TCR transgenic CD4 T cells followed by immunization of peptide in adjuvant, 
addition of anti-OX40 promoted accumulation of effector cells and importantly, resulted in 
accumulation of functionally competent memory cells, 35 days after immunization [230]. These 
data confirms the role of OX40 signaling in clonal expansion and accumulation of effector cells 
which foster the development of functional memory T cells.  
Anti-apoptotic proteins induced by OX40 signaling can also inhibit AICD in T cells. In vitro 
stimulation of WT CD4 T cells with anti-OX40 mAb was shown to enhance the expression of 
Bcl-2 and Bcl-xL, and retroviral transduction of Bcl-2 and Bcl-xL in OX40 deficient CD4 T cells 
restored the survival defect in T cells [212]. Additional studies show that, OX40 signals 
maintain the active form of Protein Kinase B (PKB), which is known to promote Bcl-2 
expression [228] and enhance the expression of survivin [229], a protein known to regulate 
G1-S transition and hence T cell division. In summary, these data suggests that OX40 
signaling promotes T cell survival beyond initial T cell priming by enhancing anti-apoptotic 
protein expression. 
 
C. OX40 in T cell differentiation  
Initial studies suggested a role of OX40 signaling in driving Th2 differentiation [17, 213, 231-
236], but later reports indicated that OX40 signals could also enhance Th1 differentiation [16, 
237-239]. The role of OX40 signaling in Th2 differentiation was shown in vitro with naive 
human CD4 T cells that were stimulated with anti-OX40 resulting in production of IL-4, and 
differentiation into Th2 cells which further produced high levels of IL-4 [232]. Additionally CD4 
T cells, stimulated with OX40L expressed on activated murine B cells, also produced IL-4 and 
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differentiate into Th2 cells [235]. OX40 costimulation could drive both Th1 and Th2 
differentiation in response to same antigen, where using TCR transgenic CD4 T cells specific 
for pigeon cytochrome C peptide, OX40 costimulation was shown to induce IL-2, IFN-γ and IL-
5 production from CD4 T cells [17]. Recently, in a transgenic mouse model where Ag is 
persistently expressed, OX40 costimulation was shown to promote Th1 differentiation of CD4 
T cells when stimulated in vitro with IL-12 and IL-18 [210]. Moreover, while OX40 costimulation 
is important in driving Th2 responses and lung pathology in asthma models [236, 240], it also 
results in CD4 T cell-mediated pathology in rheumatoid arthritis (RA) [237] and experimental 
autoimmune encephalomyelitis (EAE) [226, 241], diseases that are associated with Th1 or 
Th17 cell activation. Overall these reports, suggest that OX40 signaling does not directly 
influence T cell polarization to Th1 or Th2 phenotype, but rather enhances effector cell 
programs established early in T cell priming, perhaps as dictated by the TCR affinity for 
antigen or the surrounding cytokine milieu.   
 
D. OX40 signaling in disease 
Role in infectious diseases 
Potential role of OX40 signaling in enhancing T responses suggests that OX40 could be 
potentially targeted in vaccination strategies or therapeutic applications to promote protection 
against pathogens. In terms of fungal infection, treatment with stimulatory OX40L.Ig fusion 
protein has been shown to promote IFN-γ production by CD4 T cells and reduced eosinophilia 
and C. neoformans burden in the lung [242]. Moreover, immunotherapy with OX40L-Fc 
chimeric fusion protein in combination with anti-CTLA4 was shown to promote CD4 T cell 
proliferation, granuloma maturation, and killing of Leishmania donovani [243]. Anti-OX40 also 
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promoted SIV gp130-specific T cell and antibody responses in rhesus monkeys [244], and, 
similarly, inclusion of the OX40L gene in a plasmid DNA vaccine encoding hepatitis B surface 
antigen (HBsAg) enhanced primary CD4 and CD8 T cell responses against this antigen, as 
well as long-term memory [245]. Lastly, OX40-OX40L interactions were important for 
generation of anti-viral T cell responses to provide protection during mCMV [246] and vaccinia 
virus infection [247]. 
 
Role in tumor immunity 
The ability of OX40 agonists to regulate immune responses, as well as the expression of OX40 
on CD4 and CD8 T cells from the tumors and tumor-draining lymph nodes in mice and humans 
led investigators to examine OX40 manipulation as a treatment for cancer patients [248-250]. 
Initial pioneering work from Andrew Weinberg’s group showed that OX40 agonist mAb 
augments protection against growth of melanoma, sarcoma, breast and colon carcinoma, in 
the mouse resulting in significant improvement in the percentage of tumor-free survivors (20–
55%) [251]. Following preclinical studies have demonstrated that treatment of tumor-bearing 
hosts with OX40 agonists, including anti-OX40 mAb or OX40L-Fc fusion proteins, resulted in 
tumor regression in several tumors [248, 249, 252-254]. In addition to promoting effector T cell 
expansion, OX40 agonists have the ability to directly regulate Treg cells. There are conflicting 
reports on whether these agonists promote or diminish Treg cell responses. It is suggested 
that anti-OX40 can push Treg cells in both directions, depending upon the context of 
stimulation and the cytokine milieu [253, 255, 256] and overall immunological effects of anti-
OX40 therapy can vary based on the tumor model and multiple mechanisms can be involved 
for the anti-tumor activity of OX40 agonists. 
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The use of anti-OX40 monotherapy in a Phase 1 clinical trial in patients with solid tumors, 
showed promising results, where twelve out of 30 patients receiving OX40 agonist had 
regression of at least 1 metastatic lesion with only 1 cycle of treatment [257]. Patient toxicities 
were much milder for anti-OX40 mAbs compared to more severe toxicities, i.e., autoimmune-
like disease, colitis, etc., caused by treatment with CTLA-4 blockade (ipilimumab), and most 
frequently resulted in temporary lymphopenia. Patients receiving the OX40 agonist had an 
expansion of CD4 (non-Treg cells) and CD8 T cells with concomitant expression of activation 
markers CD38 and HLA-DR. Unlike treatment with ipilimumab, OX40 agonist treatment did not 
induce expansion of Treg cells in the blood or tumor. Moreover two out of three patients had 
IFN-γ-producing CD8 T cells following stimulation with autologous tumor cell lines in vitro, 
suggesting a tumor-specific T cell response, though the antigens they recognize remain 
unknown. Recently, two new OX40-based clinical trials have been initiated at the Providence 
Cancer Center, Phase I/II trial that combines high-dose fractionated radiation with anti-OX40 
treatment in breast cancer patients (NCT01862900) and Phase Ib trial combining 
chemotherapy (cyclophosphamide) and radiation with anti-OX40 Ab treatment in prostate 
cancer patients (NCT01303705). The anti-OX40 Ab used in these trials is of mouse origin. The 
recent development of humanized OX40L:Ig fusion protein that binds to OX40 with greater 
affinity could result in better outcomes and less side effects in the future studies using OX40 
treatment [258]. Indeed, the use of OX40 agonists in the clinic represents an exciting chapter 
in cancer immunotherapy. However, it is unlikely that anti-OX40 alone will be sufficient to cure 
all the patients or all tumor types. There is great promise that combination immunotherapy 
incorporating OX40 with other checkpoint inhibitors (PD-1 and CTLA-4), or recombinant IL-2, 
intratumoral TLR ligands, radiotherapy, and chemotherapeutics may be able to do what single 
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agents alone cannot. 
 
In conclusion 
Our aim is to understand if the signaling pathways induced by adjuvants, LPS and poly I:C 
when combined with CD134 costimulation can promote enhanced CD4 T cell expansion, 
cytokine differentiation, and memory. For this we will first analyze if LPS induced IFNαR1 
signaling and downstream chemokine pathways promote CD4 T cell expansion or 
accumulation in different lymphoid and non-lymphoid tissues. We have seen before that LPS 
induced TRIF signaling promotes T cell accumulation in non-lymphoid tissues of liver and lung, 
however the mechanism behind this is unknown. Hence studying LPS induced signaling 
pathways of type I IFN and downstream chemokines, could help us explain (1) How LPS and 
CD134 agonist synergize together to augment CD4 T cell expansion and survival (2) How 
TRIF signaling promotes T cell migration into peripheral tissues of liver and lung. Following this 
will determine, if poly I:C and CD134 agonist can be combined together, similar to poly I:C and 
anti-CD40 to promote enhanced CD4 T cell expansion and Th1 differentiation. We will also 
analyze if poly I:C and anti-CD134 combination relies on IFNαR1 signaling to promote 
enhanced T cell expansion and Th1 differentiation. For fighting challenging infectious diseases 
such as HIV, malaria and tuberculosis, Th1-type T cell immunity is crucial. Hence 
understanding, the signals induced by adjuvants, LPS and poly I:C that promote CD4 T cell 
expansion, survival, subset differentiation will allow us to harness these pathways in the future 
for design of optimal Th1 response inducing vaccines.  
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Figure 1-1 Simplified version of LPS induced TLR4 Signaling: TLR4 activation by 
LPS involves the participation of several molecules (LBP, CD14 and MD-2). Once 
activated, TLR4 induces two downstream signaling pathways, MyD88-dependent and 
MyD88-independent. The MyD88-dependent pathway is triggered by MyD88 
recruitment of TRAF6 and IRAKs, which in turn results in activation of TAK1. TAK1 
phosphorylates IKKβ, leading to degradation of IκBα and activation of NFκB. NF-κB 
translocates to the nucleus to promote the transcription of several cytokine genes. 
TAK1 also activates MAPK pathway leading to activation of JNK and p38 (not 
depicted). This leads to activation of AP-1 that dimerizes and translocates to the 
nucleus to activate cytokine genes. AP-1 and NFkB together induce transcription of 
several proinflammatory cytokines such as IL-1α/β, IL-18, IL-6, and TNFα. The MyD88-
independent pathway relies on TRIF recruitment of TRAF3. TRAF3 activates IRF3 
through TBK1 and IKKi, inducing transcription of type I interferons (IFNs) and IFN-
inducible genes. 
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Fig 1-2. Poly I:C induced signaling pathways. Figure depicts a simplified version of 
signaling pathways triggered by poly I:C. Poly I:C could be sensed by multiple receptors at 
different cellular location. TLR3 in the endosome detects extracellular poly I:C with the help 
of a cell surface co-receptor, CD14 and uses TRIF as its signaling adaptor. TRIF recruits 
TRAF6 and TRAF3. Ubiquitinated TRAF6 binds NEMO to activate TAK1. TAK1 
phosphorylates and activates MAPK, which then goes on to phosphorylate AP-1. AP-1 
dimerizes and enters the nucleus, to activate transcription of cytokine genes. On the other 
end, TAK1 activates the NEMO-IKKα-IKKβ complex and subsequently phosphorylates and 
degrades IkB, freeing NFkB to enter the nucleus and induce gene transcription. 
Additionally TRIF through TRAF3 recruits and activates TBK1 kinase (TBK1 and IKKi) that 
phosphorylates IRF3. IRF3 dimerizes and enters nucleus to induce gene transcription. 
RIG-I and MDA5 are RNA helicases that recognize poly I:C based on the structural 
differences. RIG-I detects poly I:C with 5'triphosphate cap and requires ubiquitination to be 
activated. MDA5 senses long chain poly I:C. LGP2 another RNA helicase (not depicted 
here) lacks signaling domain and is therefore believed to play a structural role in facilitating 
ligand recognition by RIG-I and MDA5. Both MDA5 and RIG-I, uses IPS-1 or MAVS 
located on mitochondrial membrane as signaling adaptor. MAVS interacts with TRAF3 and 
activates TBK1 to initiate IRF activation but depends on FADD and caspase 8 and 10 
proteolysis to activate NFkB. As a result of this signaling pathways NFkB and AP-1 
induces pro-inflammatory cytokines whereas induction of type I IFN is more stringently 
controlled (specially of IFNβ) by coordinated actions of IRF, NFkB and AP-1.  
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Figure 1-3. Type I Interferon signaling. Schematic representation of the main 
transcriptional complex induced by type I signaling. Type I IFN binds its receptor, which is 
a heterodimer consisting of the IFNAR1 and IFNAR2 chains. This activates two kinases 
(JAK1 and TYK2) associated with the receptor to phosphorylate the signal transducers 
STAT1 and STAT2, which bind each other. The STAT1 and STAT2 heterodimer 
subsequently binds IRF9 to form the transcriptionally active ISGF3 complex. ISGF3 is not 
fully active on its own, and requires additional phosphorylation from the protein kinase C 
(PKC) pathway. ISGF3 translocates to the nucleus and binds interferon responsive 
elements (IRE) within the genome, and recruits other enhancers and chromatin modulation 
complexes (not shown) to initiate interferon-induced transcriptional programs. 
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CHAPTER II: MATERIAL AND METHODS 
 
Mice 
C57BL/6 mice, TRIF-deficient, IFNαR1-/- and C57BL/6 congenic CD45.1 mice (stock numbers, 
000664, 005037, 032045 and 002014 respectively) were purchased from Jackson laboratory 
(Bar Harbor, ME). TEa CD4 TCR transgenic RAG−/− mice specific to Eα 52-68 peptide [259, 
260] and TCRβδ-/- mice [261] were bred at Jax and in our laboratory. TEa Thy 1.1 mice were 
made by crossing TEa CD4 TCR transgenic mice with Thy 1.1 mice on C57BL/6 background 
from jackson laboratory (stock number, 000406). All mice were maintained in the animal facility 
at the University of Connecticut Health Center under specific pathogen-free conditions and 
handled in accordance to National Institutes of Health federal guidelines.  
 
Immunization and Tissue Processing 
For IFNαR1 blockade experiments, ~1 x105 CD4 TEa cells isolated from pLN and spleen of 
TEa mice were i.v. transferred into C57BL/6 recipient mice. The next day mice were i.p. 
injected with 1mg/ml of anti-IFNαR1 mAb (MAR1-5A3 [262], BioXcell, West Lebanon, NH) or 
IgG control (I5381, Sigma-Aldrich, St. Louis, MO) and 4 h later immunized i.p with 100 µg Eα 
peptide (Invitrogen, Grand Island, NY or Genescript, Piscataway, NJ), 30 µg LPS (Salmonella 
typhimurium, Sigma-Aldrich, St. Louis, MO) and 7 µg of anti-CD134 mAb (clone OX86, 
BioXcell) as previously conducted [11, 19]. For simultaneous IFN-γ and IFNαR1 blockade 
experiments, mice that received TEa cell transfer as before were treated the next day with 
either anti-IFN-γ mAb (0.5 mg), anti-IFNαR1 mAb (1 mg), anti-IFN-γ+anti-IFNαR1 mAb (0.5 
mg+1 mg) or mouse IgG+rat IgG control (0.5 mg+1 mg) Ab followed by immunization.  For 
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CXCL9 blockade experiments, TEa cells were transferred into C57BL/6 recipients, as above 
following which they were immunized i.p. together with 100 µg of anti-CXCL9 mAb [195] or 
hamster IgG (0121-14, Southern Biotech, Birmingham, AL), and 8 h later a second treatment 
with anti-CXCL9 mAb or control was given. For the adoptive transfer competition experiment, 
CD4 T cells were isolated by negative isolation (EasySep™Mouse CD4+ T Cell Isolation Kit, 
StemCell Technologies, Vancouver, Canada) from WT (CD45.1+) and IFNαR-/- (CD45.2+) mice 
(both on C57BL/6J genetic background). The cells were mixed in a 1:1 ratio and 0.6x105 cells 
of WT and IFNαR-/- each were transferred into TCRβδ-/- recipients, following which the mice 
were i.p immunized next day with 1 µg S. aureus enterotoxin A (SEA) (Toxin Tech, Sarasota, 
FL), 30 µg LPS and 25 µg anti-CD134 mAb similar to previous studies [19]. To study the 
memory response to Ag+LPS+anti-CD134 combination, ~1 x105 CD4 TEa or Thy 1.1+ TEa 
cells were transferred into C57BL/6 mice, followed by the treatment with anti-IFNαR1 mAb or 
control and by immunization with Eα peptide, LPS and anti-CD134 mAb. Around day 28 to 31 
mice were re-challenged with Eα peptide and LPS, following which on day 5 or 7, mice were 
sacrificed and TEa or Thy 1.1+ TEa cells from pLN and liver were analyzed.  
 
To study the impact of poly I:C and CD134 in specific T cell expansion and cytokine 
differentiation, ~1x106 of Thy 1.1+ TEa cells obtained from the pLN and spleen were 
transferred to C57BL/6 mice, followed by treatment with anti-IFNαR1 mAb or control and 
immunization with Eα+poly I:C, Eα+anti-CD134 or Eα+poly I:C+anti-CD134 (100 µg of 
Eα peptide, 40 µg of poly I:C (Sigma-Aldrich, P0913) and 7 µg of anti-CD134 mAb)). Whereas 
to study the memory response, mice were treated as above and around day 30 or 31 they 
were re-challenged with Eα and poly:IC, following which on day 5 or 7, they were sacrificed 
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and Thy 1.1+ TEa cells from spleen and liver were analyzed. To study if CD134 costimulation 
works together with IFNαR1 signaling to promote Ag-specific CD4 T cell response, ~1x106 WT 
(Thy 1.1+ 1.2+ TEa) or CD134-/- (Thy 1.1+ TEa) cells were separately transferred into C57BL/6 
mice, followed by their treatment with anti-IFNαR1 mAb or control and immunization with 
Eα+anti-CD134. On day 7 or 8 following immunization mice were sacrificed and WT and 
CD134-/- Thy 1.1+ cells from spleen and liver were analyzed.  
 
Lymphocytes obtained from pooled peripheral lymph nodes, pLN (inguinal, axillary, and 
brachial), spleen, liver and lung were isolated similar to our previous approaches [20]. Briefly, 
pLN and spleen cells were separately crushed through 100 mm nylon mesh strainer (BD 
Falcon, Franklin Lakes, NJ), and then spleen cells were further treated with 150 mM 
ammonium chloride to lyse red blood cells. For liver and lung cells, mice were first perfused 
with PBS containing heparin (Sigma-Aldrich), then the liver was minced through cell strainers 
and cells partitioned on a 35% Percoll (GE Health Care, Piscataway, NJ, USA) gradient. The 
lungs were cut into small pieces and incubated in 1.3 mM EDTA in basic salt solution (BSS) 
without Mg2+ and Ca2+ at 37°C for 30 min with agitation, followed by collagenase (Sigma-
Aldrich) treatment at 37°C for 1 h with agitation. Lung cells were fractionated on a 44% and 
67% Percoll gradient (GE Health Care) with lymphocytes partitioning at the interface. 
Lymphocytes from all the tissues were suspended in BSS (balanced salt solution 
supplemented with HEPES, L-glutamine, penicillin, streptomycin, and gentamicin sulfate).   
For serum isolation, a few drops of blood was collected from the tail vein 3 h after 
immunization and added to the microtainer tube (BD Life Sciences, Franklin Lakes, NJ) with 
clot activator and serum gel separator. After 30 to 40 min at room temperature the tube was 
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spun at 8000 x g for 1.5 min and serum was stored at -80˚C until analysis. 
 
Flow cytometry 
For surface staining ~0.5 to 1 x 106 cells were suspended in a staining buffer (BSS, 3% fetal 
bovine serum and 0.1% sodium azide) and nonspecific antibody binding was mitigated with Fc 
block (mouse serum (Sigma), human IgG (Sigma), and anti-mouse Fc mAb 2.4G2 [263] as we 
have routinely performed [11, 264]. Cells were stained on ice for 30 min in dark and then 
washed and suspended in the staining buffer or fixed with 2% paraformaldehyde in staining 
buffer for analysis the next day. For intracellular cytokine detection, ~1 x 106 cells were 
restimulated in vitro with 5 µg Eα peptide or 50ng/ml phorbol 12-myristate 13-acetate (PMA) 
(Calbiochem) plus ionomycin (1µg/ml) (Invitrogen) at 37°C and 5% CO2 in 0.2ml of complete 
tumor medium (CTM) (minimal essential medium (MEM) supplemented with 10% fetal bovine 
serum, dextrose, salts, amino acids, and antibiotics). After stimulation the cells were washed 
with staining buffer and stained for CD4, Vα2, Vβ6. Cells were then fixed with 2% 
paraformaldehyde, permeabilized with 0.25% saponin (Sigma) and stained with anti-IFN-γ and 
anti-TNF in permeabilization buffer. For p-STAT1 intracellular staining, splenocytes were first 
treated with IgG or anti-IFNαR1 mAb (2.5 µg) for 30 minutes, following which recombinant type 
I IFN (2000 U/ml) was added to the cells for 45 minutes. Cells were fixed with 1.5% 
paraformaldehyde, following which they were permeabilized with icecold methanol for 25 
minutes (after this cells could be stored at -20° C and stained at a later time point). Before 
staining for p-STAT1 cells were washed with cold PBS to remove the methanol, and then 
stained for with CD4, Vα2, Vβ6 and anti-p-STAT1 Abs in PBS containing, 0.5% BSA and 
0.01% Na azide (phosphate buffer) for 30 minutes at room temperature. Following this, cells 
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were washed with phosphate buffer and samples were run on BD LSR II and data was 
analyzed using FlowJo 10.2 software (Tree Star, Ashland, OR). The mAbs were purchased 
from BD Pharmingen (CD3 AF700, Vβ6 APC, Vβ3 PE, CD45.1 FITC, TNF AF700), 
ebioscience (Vα2 FITC, Vα2 PEcy7, Vβ6 PE, CD45.2 APC, Armenian Hamster IgG APC or 
PE, IFN-γ PerCpCy5.5 or APC), Biolegend (CXCR3 APC or PE), BD biosciences (CD4 V450, 
p-STAT1 AF647), Invitrogen (Live dead UV Blue) or Tonbo Biosciences (Ghost Dye Red 780). 
 
In addition to above experiments we performed control experiments, where we analyzed the 
TEa cells in C57BL/6 mice at basal level without TEa cell transfer or immunization. Here, the 
average of percent TEa cells in spleen and liver of mice on day 0, were 1.19 ± 0.34 and 0.53 ± 
0.10 respectively, whereas the average of total number of TEa cells in spleen and liver were 
0.016 ± 0.005 and 0.001 ± 0.0003 (x106) respectively. In our second control, we analyzed TEa 
expansion in C57BL/6 mice that received TEa transfer as before, but no immunization. On day 
5, the average percent TEa cells in spleen and liver of mice were 0.98 ± 0.04 and 0.54 ± 0.05 
respectively, whereas the average of total number of TEa cells in spleen and liver were 0.015 
± 0.003 and 0.001 ± 7.057e-005 (x106) respectively. Data in both these experiments is derived 
from 1 experiment, n = 3 mice represented as Mean ± SEM. Overall this shows that without 
TEa transfer and immunization, TEa cells in lymphoid (spleen) and non-lymphoid tissue (liver) 
are very low in numbers and for optimal expansion, mice need to receive both TEa transfer 
and immunization. 
 
ELISA, SDS-PAGE and Immunoblotting  
Mouse IFN-β ELISA kit was from PBL assay science (Piscataway, NJ), mouse CXCL9/MIG 
	  46	  
	  
DuoSet kit (DY492) or CXCL10/IP-10/CRG-2 DuoSet ELISA kit (DY466) was from R&D 
Systems (Minneapolis, MN). All ELISA’s were performed according to the manufacturer’s 
instructions, and absorbance was determined at 450 nm using a Bio-Rad iMark (Bio-Rad, 
Hercules, CA) or Clariostar microplate reader (BMG Labtech, Cary, NC). The concentrations 
were calculated using a standard curve line of best fit on Microplate Manager Software (Bio-
Rad) or MARS data analysis software (BMG Labtech). Briefly, for immunoblotting ~40 µg 
protein of liver tissue lysate suspended in denaturing SDS sample buffer were resolved on 4–
15% SDS PAGE, transferred onto 0.2 µm nitrocellulose membrane using a semi-dry blotting 
device (Bio-Rad) and finally probed with anti-CXCL9 antibody (R&D Systems, AF-492-NA). 
The membrane was washed, incubated with secondary HRP-conjugated rabbit anti-goat 
antibody (Santa Cruz Biotechnology, Dallas, TX), washed and then band detection was 
performed using ECL plus (GE Healthcare Life Sciences). Recombinant CXCL9 (R&D 
Systems, 492-MM) was used as a positive control and anti-β-actin was used as the loading 
control (Abcam, Cambridge, MA). 
 
Real Time-PCR 
On day 5 the liver tissue was harvested and RNA was extracted from roughly 30 mg of liver 
tissue using RNeasy mini kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. 
The RNA was reverse transcribed to cDNA using iScript cDNA synthesis kit (Bio-Rad) and a 
Real-Time quantitative PCR measurement of cDNA was then performed using iTaq Universal 
SYBR Green Supermix (Bio-Rad) and a CFX96 real-time PCR instrument (Bio-Rad). For 
analysis, gene expression for both anti-IFNαR1 Ab and IgG treated group were normalized to 
β-actin and the fold change was calculated by subtracting the gene expression of IgG treated 
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group from anti-IFNαR1 group. PCR primers were generated by inputting the NCBI accession 
number for each gene in the primer bank website (https://pga.mgh.harvard.edu/cgi 
bin/primerbank/new_search2.cgi) to get a validated forward and reverse primer sequence that 
was then purchased from Integrated DNA technologies, IDT (Coralville, Iowa) (Table 1).  
 
Transwell Assay 
Briefly, 24-well plate containing transwell inserts (6.5 mm diameter, 5 µm pores; Corning, 
Lowell, MA) were coated with 50 µl of 10 ng/ml murine fibronectin (Innovative research, Novi, 
MI) and incubated for 1 h at 37°C and 5% CO2. The solution was removed and inserts were 
dried for 2 h at 37°C (without CO2). The pLN lymphocytes were harvested from immunized 
mice on days 5 or 11 and suspended in CTM  (without the FBS) supplemented with 0.5 % 
BSA. The lower chamber of the transwell was filled with 600 µl of 1000 ng/ml of CXCL9, 
CXCL10 or CXCL1 in CTM (Peprotech, Rocky Hill, NJ). The lymphocyte suspension (~0.5 to 
1x106 cells) was then added to top of the insert and allowed to migrate for 30 min at 37°C and 
5% CO2. After migration the cells on the top and bottom of the insert were collected, washed 
with the staining buffer and labeled with fluorescently labeled antibodies to analyze the percent 
TEa cells by flow. The data is represented as ratio of percent CD4 TEa cells in the bottom of 
the well to percent CD4 TEa cells on top of the well. 
 
Statistical analysis  
The data between groups were compared by unpaired, two-tailed t-test by using GraphPad 
Prism (GraphPad Software, San Diego, CA, USA) where * p < 0.05, ** p< 0.01, *** p < 0.001, 
***** p < 0.0001. 
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CHAPTER III: 
Optimal CD4 T cell priming after LPS-based adjuvanticity with CD134 costimulation 
relies on CXCL9 production 
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Abstract 
 
Lipopolysaccharide is a powerful adjuvant, and while LPS mediated TLR4 signaling has been 
exquisitely delineated, the in vivo mechanism of how TLR4 responses impact T cell priming is 
far less clear. Besides costimulation, TNF and type 1 IFN are dominant cytokines released 
after TLR4 activation and can shape T cell responses but other downstream factors have not 
been extensively examined. Depending upon context, we show that IFNαR1 blockade resulted 
in minor to major effects on specific CD4 T cell clonal expansion and Th1 differentiation. To 
help explain these differences, it was hypothesized that IFNαR1 blockade would inhibit specific 
T cell migration by reducing chemokine receptor signaling, but specific CD4 T cells from 
IFNαR1 blocked mice were readily able to migrate in response to specific chemokines. Next, 
we examined downstream factors and found that type 1 IFN signaling was necessary for 
chemokine production when mice were immunized with specific Ag with LPS and CD134 
costimulation. IFNαR signaling promoted CXCL9 and CXCL10 synthesis suggesting that these 
chemokines might be involved in the LPS and CD134 costimulation response. After 
immunization we show that CXCL9 blockade inhibited CD4 T cell accumulation in liver but also 
in lymph node even in the presence of elevated serum IFN-β levels. Thus, while type 1 IFN 
might have direct effects on primed CD4 T cells, the downstream chemokines that play a role 
during migration also impact T cell clonal expansion. In sum, CXCL9 production is a key 
benchmark for productive CD4 T cell vaccination strategies. 
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Introduction 
 
Adjuvanted vaccines have promoted worldwide health through immunization programs [265]. 
One of the key ingredients in an adjuvanted vaccine is the adjuvant itself [266]. Typically 
adjuvants are ligands for pattern recognition receptors that stimulate appropriate levels of 
inflammation to activate antigen presenting cells, which prime and costimulate specific CD4+ T 
cells to help B cells synthesize specific antibodies or stimulate cytotoxic T cells to kill infected 
cells. Not surprisingly, most data from model systems show that immunization without an 
adjuvant fails to promote these characteristics of durable humoral and cellular immunity [267, 
268]. Thus, a major area of investigation is centered on understanding the immune signals that 
emanate from an adjuvant or costimulatory responses that stimulate and/or sustain specific T 
cell longevity [269-271]. 
Many adjuvants are ligands for TLR and perhaps the most notable example is the TLR4 ligand 
bacterial LPS of which its derivative MPL in combination with alum is FDA approved in an 
adjuvanted HPV vaccine [272-274]. Seminal work has shown that TLR4 signaling relies on the 
MyD88 and TRIF adaptors [34], and the use of MPL was at least partially based on its 
tendency to signal through TRIF over MyD88 [4, 13]. In our model we used LPS since it 
promotes lasting memory CD4 T cell responses over that with MPL [275]. Important work is 
investigating less toxic variants of LPS manufactured by chemical degradation, synthetic 
assembly or genetically modification for their potential use as vaccine adjuvants [276], but a 
fundamental understanding of LPS-based CD4 T cell responses is critical for vaccine 
development as an approach to identify important pathways for T cell survival that might be 
characteristic of newly developed adjuvants. 
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Ultimately, TLR4 activation on antigen presenting cells, similar to the other TLRs, increases 
the expression of T cell costimulatory ligands [277], cell maturation [278], and also triggers 
release of a complex cytokine network [279]. Specifically, LPS adjuvanticity requires dendritic 
cells for optimal T cell priming [11], and the TLR4 adaptors largely play non-overlapping roles 
in the context of providing queues for T cell differentiation and survivability [280, 281]. The 
outcome of TLR4 stimulation or the use of LPS during immunization impacts humoral immunity 
[282], prevents peripheral T cell tolerance and promotes long-term T cell memory as found in 
different tissues of the body [10, 46, 283, 284]. Perhaps most striking is the addition of 
costimulation, which potently increases the effectiveness of T cell priming. One example is 
CD134 (OX40) costimulation supplied in the form of enforced costimulation with an agonist 
mAb [19], and others such as CD40 and CD137 (4-1BB) also have similar effects [200, 285, 
286]. Enforced costimulation is already in use for cancer immunotherapy validating its 
importance and under the right circumstance could be used to stimulate vaccine development 
for infectious disease or further improve cancer immunotherapy when combined with TLR 
ligands [18, 276, 287, 288]. Thus, triggering TLR together with enforced costimulation provides 
a powerful combination to prime T cell immunity, and the mechanism behind it is not only 
unclear but also vitally important to understand, so that the pathways leading to adverse 
events can be separated from the beneficial ones. 
A major response to different adjuvant and enforced costimulation platforms are similar 
cytokine outputs. As an example, IL-6 and IL-1β are typically produced and these factors 
regulate T cell responses but this commonality largely precludes them from explaining the 
differences in adjuvant responses. Therefore, probing downstream from the initial cytokine 
release to find factors that might be different between responses, and perhaps exert 
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specialized effects on T cell function, is critical to advance vaccine development. Our goal was 
to study this idea by examining type 1 IFN, which is not as widely produced as compared to 
TNF, but has been previously implicated in specific adjuvant responses [139, 289, 290]. Thus, 
we set out to determine if the potent LPS and anti-CD134 stimulation protocol relied on type 1 
IFN or perhaps the downstream mediators in this complex cytokine network.  
By tracing T cell and cytokine responses we found that specific antigen and low levels of LPS 
with anti-CD134 immunization exerted a strong survival signal on specific CD4 T cells in LN, 
liver and lung, while type 1 IFN release was rapid and robust. The role of type 1 IFN was 
context dependent, but nevertheless T cells without IFNαR were potently handicapped when 
competing against WT T cells. Our data points to the downstream chemokines that play a role 
in maintaining specific T cell accumulation and suggests that testing for a precise cytokine and 
chemokine network might be an important benchmark for the effectiveness of immunization 
strategies and immunotherapy. 
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Results 
Antigen, LPS and CD134 costimulation synergize to promote specific T cell clonal 
expansion and type 1 IFN production 
The adjuvant LPS in combination with CD134 costimulation promotes robust CD4 and CD8 T 
cell expansion in response to S. aureus enterotoxin [200], as well CD4 T cell memory 
formation using a model Ag in place of enterotoxin [291]. To study this mechanism we 
transferred CD4 TCR transgenic T cells specific for Eα 52-68 peptide (TEa) into C57BL/6 
recipient mice and, similar to an immunotherapy strategy, immunized i.p. the next day (day 0) 
with LPS, anti-CD134 (agonist mAb, OX86) and Eα 52-68 peptide followed by specific T cell 
detection (TCR Vα2 Vβ6) on day 11 or 12 (Fig. 3-1A). By day 11 or 12 synergistic CD4 T cell 
clonal expansion and survival was detected in the liver, which was highest with the 
combination of peptide with LPS plus CD134 in comparison to peptide plus CD134 
costimulation, or LPS (Fig. 3-1B). Since LPS induces type 1 IFN secretion [292], we tested if 
LPS and CD134 together increased type 1 IFN levels compared to either alone with peptide 
stimulation. Three hours after immunization, serum was collected and examined for IFN-β 
levels by ELISA (Fig. 3-1C). As predicted CD134 costimulation with LPS induced the highest 
IFN-β levels, suggesting that IFN-β may play a role in supporting the T cell response in our 
vaccine model. 
In previous work, LPS was shown to promote effector CD8 and CD4 T cell accumulation in 
non-lymphoid tissues through the TRIF adaptor [20, 264], whereas Lipid-A-induced type 1 IFN 
signaling through TLR4-TRIF mediated CD4 T cell expansion in spleen [13, 47]. Similar to our 
approach, biologics are being combined with TLR agonists for immunotherapy of cancer and 
infectious disease vaccines [271, 276, 293, 294] and it was thus reasoned that a key cytokine 
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might be type 1 IFN. To determine if type 1 IFN was involved in the LPS and CD134 
costimulation platform, the MAR15A3 mAb specific to the IFNαR1 subunit receptor [262] was 
used to block IFNαR signaling. Although IFNαR signaling is complex there is a substantial role 
for STAT1 phosphorylation [295], which in our study was inhibited in the presence of IFNαR1 
blockade (Fig. 3-2A). Based on these data IFNαR1 was blocked in vivo using MAR15A3 mAb 
during the immunization approach described in Figure 1A. As expected the levels of liver IFN-
β, measured by qRT-PCR (Fig. 3-2B, left panel), were decreased but surprisingly, serum IFN-β 
levels significantly increased in the blocked mice (Fig. 3-2B, right panel). Thus, blocking the 
type 1 IFN receptor uncouples a positive feedback loop previously described [107] as there is 
a significant reduction in IFN-β transcription, but IFN-β protein levels increase systemically due 
to blocked receptor mediated internalization. Hence, these data supports the notion that 
IFNαR1 blockage is effective and might play a role in the LPS plus anti-CD134 immunization 
approach. 
To test this idea two groups of mice were immunized with LPS, anti-CD134 plus specific 
peptide; one group received Control IgG and the other anti-IFNαR1 mAb. On day 6 after 
immunization the peripheral LNs (pLN) were examined and showed a significant reduction in 
expansion, or survival, of the specific CD4 T cells when IFNαR1 was blocked (Fig. 3-2C, upper 
panels). This was the case for frequency and cell number, but in liver there was only a trend 
largely due to an outlier (Fig. 3-2C, lower panels). To test if host cells required IFNαR1 
signaling, IFNαR1-/- recipients were used in place of C57BL/6 wild type (WT) recipients. In this 
case, there was a significant reduction in percent of Ag-specific CD4 T cells in liver of IFNαR-/- 
mice on day 5 after immunization, but no difference was found in the pLN and lung (Fig. 3-2D). 
However, the total number of TEa cells were significantly reduced in both liver and lung of 
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IFNαR-/- mice and reduced to almost 50 percent in the pLN (Table 2).	  To further understand 
how IFNαR signaling in specific-CD4 T cells impacts T cell expansion, we set up an 
experiment where WT and IFNαR-/- specific CD4 T cells competed against each other for 
expansion in the same host. To increase the breadth and robustness of the T cell priming, S. 
aureus enterotoxin was used to model an oligoclonal response rather than a single TCR 
specific system. S. aureus enterotoxin A (SEA) potently stimulates TCR Vβ3 expressing CD4 T 
cells [43] and is regarded as a potential cancer therapeutic [296-298]. Thus, WT CD45.1+ 
mixed with IFNαR1-/- CD4 T cells were transferred into TCR βδ-/- mice, which prevented 
competition from endogenous T cells, and then i.p. immunized with SEA, LPS and anti-CD134 
(Fig. 3-3A). On days 7 or 8 after immunization, the IFNαR1-/- cells were completely 
outcompeted by the WT Vβ3 T cells (Fig. 3-3B). This was the case for pLN and liver and the 
same was also true for the Vβ3 T cells, 15 days after immunization (Fig. 3-3C). Lastly, the 
frequency data mirrored total cell numbers (Table 3). The non-specific WT Vβ14 T cells were 
unaffected in pLN, but they increased in the liver on day 15 significantly in comparison to 
IFNαR1-/- T cells likely due to organ inflammation (data not shown. This is similar to other 
systems where unrelated T cells report to inflamed sites [299]. Thus, specific CD4 T cells 
deficient in IFNαR signaling were profoundly handicapped when competing against WT cells. 
Nevertheless, this dramatic dependency on IFNαR1 was smaller when the host was IFNαR1 
deficient (Fig. 3-2D), or in the presence of IFNαR1 blockade by therapy (Fig. 3-2C). Overall 
these data suggests that, IFNαR1 signaling in both specific CD4 T cells (Fig 3-3) as well non-
specific cells (Fig. 3-2D) could enhance specific T cell expansion. Further studies comparing 
the how IFNαR signaling in specific CD4 T cells versus non-specific cells of the host, impact T 
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cell expansion are needed, but clearly anti-IFNαR1 therapy could be used to suppress CD4 T 
cell responses.  
We next assessed if IFNαR signaling can influence the effector function of specific CD4 T 
cells. For this we analyzed, intracellular levels of IFN-γ in lymphocytes isolated from the 
experiment done in Fig. 2-2C and Fig. 2-2D. As shown in Fig. 3-4A, left panel treatment with 
anti-IFNαR1 mAb reduced the percentage and total number of IFN-γ expressing Ag-specific	  
(Vα2+	  Vβ6+	  TEa)	  CD4 T cells in pLN after Eα peptide stimulation in comparison to the control 
treated mice. Similar, but less significant impact was also seen in percentage of IFN-γ 
expressing non-specific (Vα2-­‐	  Vβ6-­‐	  CD4) T cells after PMA+Ionomycin stimulation (Fig. 3-4A, 
right panel). However, the total number of IFN-γ expressing non-specific cells were significantly 
reduced in pLN with anti-IFNαR1 treatment. In liver and lung, IFN-γ production from specific or 
non-specific CD4 T cells was not much impacted with IFNαR1 blockade (data not shown). In 
comparison to IFNαR1 Ab blockade, analysis of cytokine expression from IFNαR-/- mice from 
experiment done in Fig 2-2D, showed that the percentage of IFN-γ expressing specific	  CD4 T 
cells were significantly reduced in liver after Eα peptide stimulation in comparison to WT mice 
(Fig. 3-4B, left upper panel). Similarly, the total number of IFN-γ expressing specific CD4 T 
cells were also significantly reduced in liver of IFNαR1-/- mice (not shown). The percentage 
(Fig. 3-4B, left middle panel) and total number of IFN-γ expressing specific CD4 T cells (not 
shown) in pLN of IFNαR-/- mice also trended towards reduction but did not reach significance. 
In comparison to pLN and liver, the percent (Fig. 3-4B, left lower panel) and total number of 
IFN-γ expressing specific CD4 T cells (data not shown) in lung of IFNαR1-/- mice were not 
impacted.  However, the percentage of IFN-γ expressing non-specific (Vα2-­‐	  Vβ6-­‐	  CD4) T cells 
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were significantly reduced in pLN and lung after PMA+Ionomycin stimulation and the percent 
of IFN-γ+ non-specific CD4 T cells also trended towards reduction in the liver (Fig. 3-4, right 
panels). The total number of IFN-γ expressing non-specific CD4 T cells were significantly 
reduced in pLN and lung of IFNαR-/- mice after PMA+Ionomycin stimulation, whereas in liver, 
they were not significantly impacted (data not shown). Thus overall, the results from Fig. 3-3, 
indicate that IFNαR signaling in specific CD4 T cells is required to promote their expansion in 
pLN and liver, whereas results from Fig. 3-4 suggest that, IFNαR signaling in non-specific cells 
of host, such as APCs may impact Th1 differentiation in specific as well as non-specific CD4 T 
cells. 
 
Downstream mediators of type 1 IFN and their function on effector CD4 T cells 
The data above suggests that type 1 IFN blockade might inhibit a downstream pathway in CD4 
T cells during this immunization approach. In fact, previous data from our lab showed that 
TRIF signaling in host cells enhances CXCR3 expression on specific CD4 T cells to 
presumably allow their migration to the peripheral tissue of liver [20]. 
To understand how IFNαR signaling impacts T cell accumulation, we examined if it could 
enhance the migration of CXCR3+ specific-CD4 T cells in pLN and liver. For this we analyzed 
CXCR3 expression on T cells from experiments done in Fig. 3-2C. We saw that, IFNαR 
signaling promoted the accumulation of CXCR3+ Ag-specific (Vα2+	  Vβ6+) as well as non 
specific (Vα2-­‐	  Vβ6-­‐) CD4 T cells in pLN (Fig. 3-5A, upper panel) and anti-IFNαR1 treatment 
reduced the percent of CXCR3+ specific CD4 T cells marginally, however it significantly 
reduced the percent of CXCR3+ non-specific CD4 T cells. Importantly, the total number of 
CXCR3+ specific and non-specific CD4 T cells were significantly reduced in pLN after anti-
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IFNαR1 treatment (Fig 3-5A, lower panel). This suggests that IFNαR signaling may promote 
migration of CXCR3+ specific as well as non-specific CD4 T cells in pLN, however, our data in 
Fig. 3-2C shows that IFNαR1 blockade reduced the accumulation of specific CD4 T cells, but 
had no impact on non-specific CD4 T cells (data not shown). Moreover,	  IFNαR1 blockade did 
not influence the percent and total number of CXCR3+ specific or non-specific CD4 T cells in 
liver, suggesting that CXCR3 expression cannot not explain how IFNαR signaling promotes 
expansion or T cell accumulation to pLN and the liver.	  
We nevertheless sought to determine if the CXCR3 receptor on Ag-specific T cells was 
functional during our vaccine immunization. To study this, day 6 pLN cells from immunized 
mice were placed in the upper chamber of a transwell and various chemokines in the lower, 
and after 30 minutes we determined the percent of specific TEa CD4 T cell that migrated into 
the lower well (Fig. 3-6A). Based on a ratio of TEa CD4 T cell percentage in the bottom over 
the percent from the top well, it was clear that specific migration was minimal in media alone or 
with irrelevant chemokine CXCL1 (Fig. 3-6B). However, in response to CXCL9 or CXCL10 the 
ratios were about 3 whether or not the cells were from IFNαR1 blocked mice. Very similar data 
were generated using Day 11 pLN cells (Fig. 3-6C) suggesting that CXCR3 was functional and 
certainly the response to CXCL9 and CXCL10 was intact in the presence of IFNαR1 blockade. 
Since IFN-β driven chemokine receptor function was not impaired in our migration assay (Fig. 
3-6), we hypothesized that IFNαR1 blockade inhibited chemokine production rather than 
receptor expression. Using qRT-PCR for CXCL9 and CXCL10 it is clearly shown that liver 
mRNA expression for both chemokines was significantly inhibited on days 2 and 5 after 
IFNαR1 blockade (Fig. 3-7A). CXCL11 is also a ligand for CXCR3, but C57BL/6 mice do not 
possess a functional CXCL11 gene [169, 170]. To further test this idea, CXCL9 protein levels 
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were determined by immunoblot using day 5 liver lysates and similar to the PCR data there 
was a consistent reduction in the CXCL9 protein levels after IFNαR1 blockade (Fig. 3-7B). 
Finally, by measuring serum CXCL9 and CXCL10 levels from the experiment in Fig. 3-2D, we 
showed a significant reduction in the IFNαR1-/- mice, but importantly an increase in IFN-β (Fig. 
6C). Secondly, we also found significantly reduced serum CXCL9 in immunized TRIF-deficient 
mice (Fig. 3-7D, left panel) further demonstrating the positive feed-forward loop of IFN-β 
driving CXCL9. Lastly, we assayed the remaining serum samples from Fig. 3-1C and found 
that LPS, but not CD134 costimulation, was critical for CXCL9 production when TEa CD4 T 
cells were activated with the cognate peptide (Fig. 3-7D, right panel).  
In sum, these data suggest that the adjuvant response mediated by TLR ligands might provoke 
IFN-β to increase CXCL9 and CXCL10 synthesis thereby promoting adjuvanted T cell 
responses. 
 
CXCL9 dominates over IFN-β to enhance specific T cell accumulation 
To test the hypothesis that CXCL9 and/or CXCL10 play a role in adjuvanting T cell responses, 
CD4 TEa recipient mice were immunized with Eα peptide plus LPS and CD134 costimulation 
in the presence of CXCL9 and CXCL10 blockade. While the effects with CXCL10 blockade 
were trending perhaps due to incomplete inhibition (data not shown), there was nevertheless a 
statistically significant inhibition of specific CD4 T cell accumulation with CXCL9 blockade (Fig. 
3-8A). Both the peripheral LN and the liver contained proportionally fewer specific CD4 T cells, 
and the lung was less impacted but certainly trended towards significant inhibition. Moreover 
the absolute number of TEa cells, were also significantly reduced in pLN after CXCL9 
blockade (Table 4).  
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To understand how CXCL9 promotes T cell accumulation, we analyzed if CXCL9 enhances 
the specific CD4 T cell migration by recruiting CXCR3 expressing specific T cells. For this we 
analyzed the CXCR3 expression on specific CD4 T cells from experiments done in Fig. 3-8A 
and as shown in Fig. 3-8B, CXCL9 blockade significantly reduced the percent and total 
number of CXCR3+ specific CD4 T cells in pLN compared to the control treated mice. This 
suggests that CXCL9 may enhance specific CD4 T cell accumulation in pLN by promoting the 
migration of CXCR3+ specific T cells. However, if CXCL9 enhanced the migration of specific T 
cells to pLN, it would result in reduced T cell numbers to liver and lung tissues, but that was 
not the case (Fig. 3-8A). Moreover, CXCL9 did not impact percent or total number of CXCR3 
expressing specific CD4 T cells in liver and lung tissue (data not shown) further indicating that 
mechanisms other than T cell migration may be responsible for CXCL9 mediated T cell 
accumulation. 
We next analyzed if CXCL9 impacts T cell accumulation, by promoting T cell proliferation. To 
test this we analyzed Ki67 expression (a nuclear Ag used as a marker of cell proliferation) in 
specific T cells from experiments done in Fig. 3-8A. Our results indicate that CXCL9 does not 
influence the percent or total number of Ki67 expressing specific-CD4 T cells in pLN, liver or 
lung (data not shown). Thus, CXCL9 induced T cell accumulation is not a result of increased T 
cell proliferation. CXCL9 may also influence T cell accumulation by promoting T cell survival or 
preventing activation-induced cell death (AICD), which we have not analyzed. The mechanism 
of how CXCL9 promotes specific CD4 T cell accumulation to lymphoid (pLN) and non-
lymphoid tissues (liver and lung) is important to understand, if one has to target CXCL9 in T 
cell vaccination strategies and we plan to address it in our future studies. 
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Collectively, these data shows that CXCL9 operates in multiple sites in the immune system 
and increases clonal expansion and accumulation of stimulated specific CD4 T cells. 
Mechanistically, it is possible that IFN-β induces CXCL9, and CXCL9 feeds back to increase 
IFN-β resulting in T cell accumulation through IFNαR1, which would be supported by the data 
in Figures 3-2 and 3-3. Thus, if this postulate were correct CXCL9 blockade should inhibit IFN-
β production. As shown at the time point tested during T cell priming, IFN-β was not reduced 
as CXCL9 was blocked (Fig. 3-8C, left panel). Hence, specific CD4 T cell expansion was 
significantly inhibited when CXCL9 was blocked even when IFN-β was available. Lastly, 
CXCL9 blockade actually increased serum CXCL9 as measured by ELISA (Fig. 3-8C, right 
panel), which might be a function of antibody protection of CXCL9.  
In sum, CXCL9 blockade significantly impaired the specific CD4 T cells from accumulating in 
lymphoid and non-lymphoid tissues demonstrating a role, not only during migration, but also in 
assisting clonal expansion or accumulation. 
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Discussion 
 
LPS triggering of TLR4 is known to amplify antigen-specific CD4 and CD8 T cell responses 
[10], which is potently enhanced by enforcing costimulation [19]. Although roles for pro-
inflammatory cytokines have been suggested [11, 300-302], a mechanistic pathway leading to 
specific T cell survival remains unknown [303]. Here, we tested a role for type 1 IFN in a 
powerful vaccine and immunotherapy platform consisting of anti-CD134 agonist mAb and low 
levels of LPS mixed with specific antigenic peptide. Depending upon the context, Type 1 IFN 
was important, but mainly because it induced production and release of CXCL9 to support 
specific CD4 T cell accumulation in lymph node and liver after immunization. Regardless of the 
IFN-β levels, the optimal adjuvant effect of LPS depended upon CXCL9 even with added 
costimulation. It is proposed that CXCL9 production is an important benchmark for vaccine 
efficacy and perhaps immunotherapy. 
In our immunization platform the TLR4 ligand LPS with CD134 costimulation induced type 1 
IFN, but without LPS/CD134 activation the specific T cells did not survive which correlated with 
low levels of type 1 IFN and CXCL9 (Figs. 3-1 and 3-7). Related to our work a recent study 
demonstrated the importance of type 1 IFN signaling in lipid A induced T cell clonal expansion 
wherein providing exogenous IFN-β rescued diminished splenic Ag-specific T cell expansion in 
TRIF-deficient mice [47]. Similar to this study, previous results from our lab demonstrated that 
CD40 activation was capable of rescuing liver CD8 T cells in TRIF-deficient mice after LPS 
adjuvanticity [20]. Thus, we postulated that bypassing IFNαR signaling during immunization 
would impact T cell expansion but it was unclear if this would depend upon specific T cells or 
host cells such as APCs expressing IFNαR.  
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To study the mechanism of how type 1 IFN impacts T cell expansion we used several 
approaches. Analogous to a therapeutic setting, a blocking mAb resulted in a significant 
reduction in percent and number of specific pLN CD4 T cells, while a decrease was trending in 
the liver (Fig. 3-2C). In contrast, WT specific CD4 T cells in IFNαR1-/- mice displayed a 
significant reduction in percent specific-CD4 T cells in liver, but no difference was seen in pLN 
and lung (Fig. 3-2D). However, the total number of specific CD4 T cells were significantly 
reduced in liver, lung and reduced to almost 50 percent in pLN of IFNαR1-/- mice (Table 2). 
Thus, IFNαR signaling in both specific T cells as well as non-specific cells of the host could 
contribute to the specific CD4 T cell expansion. However, it is clear that IFNαR signaling in T 
cell is essential for specific CD4 T cell accumulation to pLN and liver, as seen in the 
competition model where WT specific T cells were far superior to IFNαR1-/- specific T cells in 
expansion (Fig. 3-3B/C).	  One of the caveats here, is WT T cells could seed differently in 
tissues in comparison to IFNαR-/- T cells resulting in some difference in their expansion. 
However, since we transferred only 0.6x105 cells each of WT and IFNαR1-/- T cells, we may 
not be able to accurately assess if the cells seeded equivalently on day 0 after transfer.	   
Secondly there is no way of finding if the T cells migrated equivalently to all organs or sites of 
the body.	  	  
We also show that IFNαR signaling impacted Th1 differentiation, where signaling in non-
specific cells of the host was essential to promote IFN-γ production in specific CD4 T cells 
(pLN and liver) as well as non-specific CD4 T cells (pLN and lung) (Fig. 3-4B).  
Thus, these three approaches exemplify how context is critical in determining the role of 
immune pathways. Specifically, the competition study showed an impressive difference, and 
while not as apparent in the other systems, there was some role for IFNαR during LPS and 
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CD134 immunization. Ultimately, these data speak to the importance of using multiple systems 
of neutralization to obtain the range of possibilities that can occur, versus those that occur 
during therapy. Much has been gained with the use of genetically altered murine models, but 
neutralization studies with blocking reagents might best approximate what occurs in patients 
treated with biologics.  
To understand a mechanism of how type 1 IFN signaling influences T cell responses we 
examined several cytokine receptors downstream of TLR and CD134 activation. CXCR3 is 
induced by stimulation of TLR4 through TRIF signaling and might explain the lack of specific 
CD4 T cell accumulation in certain organs like liver since CXCR3 is known to mediate T cell 
migration into liver [161, 196, 304, 305] and recently shown to promote T cell migration across 
the tumor vasculature [304]. Our data show, that regardless of IFNαR blockade the specific 
CD4 T cells responded to the chemokines, CXCL9 and CXCL10 in a specific fashion (Fig. 3-6). 
Thus, faulty CXCR3 driven migration did not explain the basis for type 1 IFN mediated 
responses, suggesting that CXCR3 remained functional but perhaps its ligands were 
diminished after IFNαR neutralization. This is important since the ligands of CXCR3 are known 
to optimize Th1 responses in dLN by interacting with dendritic cells [197]. In our model, CXCL9 
promoted T cell accumulation to pLN as well as in liver and lung, however it did not enhance 
Th1 differentiation (data not shown). Our vaccine model employs CD134 agonist, which as 
mentioned before, could induce Th1 differentiation [16, 17, 237, 239]; and possibly rescue it 
after CXCL9 blockade, therefore the results between these studies cannot be directly 
compared. Chemokine CXCL10 has also been shown to mediate positioning of CXCR3+ T 
cells in LN to assist in CD4 T cell priming during influenza vaccination [264], suggesting that 
even in a model of vaccine derived antigen CXCR3 ligands facilitate Th1 responses. Thus, it 
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was hypothesized that T cell function attributed to type 1 IFN in response to LPS and CD134 
costimulation might actually occur through CXCR3 stimulation. IFNαR blockade significantly 
reduced CXCL9/10 transcript levels, and IFNαR-/- hosts also contained significantly reduced 
CXCL9/10 serum levels. Nevertheless, IFNαR-/- hosts contained high amounts of serum IFN-β 
(Fig. 3-7C). This suggests that the transferred specific T cells in the IFNαR-/- hosts had ample 
access to IFN-β while the host APCs did not since they were IFNαR-/- (Fig. 3-2D). Thus, an 
interesting question arises asking if the reduced T cell response in IFNαR-/- mice was due to 
minimal levels of CXCL9/10 or because the APCs could not respond to IFN-β. To address this 
issue anti-CXCL9 mAb was used to block CXCL9 [195] during immunization, which 
demonstrated that specific CD4 T cell accumulation was significantly inhibited in LN and liver, 
even though IFN-β serum levels remained similar to an IgG control group (Fig. 3-8C).  
On the other hand, when there are high IFN-β levels as seen in IFNαR-/- hosts (Fig. 3-7C), the 
specific T cells have greater access to IFN-β, which functionally results in an increased dose of 
the cytokine despite modest amounts of CXCL9. Specifically, a higher than WT level of serum 
IFN-β might bypass the role of other downstream pathways making the cytokines appear 
redundant. Thus, high levels of type 1 IFN might promote T cell survival when other survival 
factors are limiting and IFN-β has been shown to directly induce T cell survival in vitro [48].  
Similarly, IFN-β stimulates dendritic cells [306], but IFNαR was not required for dendritic cell 
maturation after LPS treatment, but rather a TLR4 TRIF-based MAP kinase intrinsic signal was 
critical [307]. Similarly, we previously observed a potent LPS adjuvant effect on LN T cells in 
TRIF-deficient mice, even though liver responses were impaired [20]. Thus, our platform of low 
levels of LPS administration can prime dendritic cells void of IFNαR signaling while enforcing 
CD134 costimulation on specific CD4 T cells provides a tool to enhance CD4 T cell priming. 
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In conclusion, shows that specific CD4 T cells were impaired in their ability to accumulate in 
LN or liver during CXCL9 blockade. A lone role in migration would have logically led to an 
increased number of the specific T cells in LN with reduced numbers in liver, but we observed 
a reduction in specific T cell numbers in both of the compartments. Thus, it will be important to 
test if CXCL9 breaks activation-induced cell death directly in T cells perhaps by enhancing 
interactions with dendritic cells [197]. Nevertheless, a major challenge in this regard will be to 
detect dead specific T cells in vivo that have not bound CXCL9. The other possibility is that 
CXCL9 enhances cell cycle progression leading to greater proliferation but we found no 
significant difference in Ki67 staining on day 6, with or without CXCL9 blockade (data not 
shown). Our study, however does demonstrate that CXCL9 promotes CD4 T cell accumulation 
substantially adding to the idea that CXCL9 facilitates memory responses by facilitating 
positioning of CM CD8 T cells with dendritic cells in LN [178, 198]. 
 
Therefore, CXCL9 has pleotropic functions and understanding its cellular source, timing of 
release and the cells that it targets will add greatly to controlling cellular immunity for 
biomedical benefit. In particular, CXCL9 release might be especially important in vaccine 
adjuvant development and also in assessing enforced costimulation protocols for 
immunotherapy.  
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Figure 3-1. Antigenic peptide administered together with LPS and CD134 
agonist promotes maximal T cell expansion and Type I IFN production.  
Ag-specific T cells (TEa) were adoptively transferred to C57BL/6 mice that were 
immunized the next day with either Eα peptide, Eα+LPS, Eα+anti-CD134, 
LPS+anti-CD134 or Eα+LPS+anti-CD134. On days 11 or 12 the percentage of 
CD4 T cells expressing TCR Vα2+ Vβ6+ (Ag-specific T cells) in the liver were 
analyzed by gating on live cells. (A) Shows a representative gating strategy and 
(B) is the quantitated data. (C) Three hours after immunization the serum levels of 
type I IFN (IFN-β) were determined by ELISA. The data is pooled from 3 
independent experiments. Fig. 1B. p value, * < 0.05. Fig 1C. p value, ** 0.01, **** < 
0.0001. Error bars represent SEM of all experiments in that group. 
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Figure 3-2. The impact of Type I IFN signaling on Ag-specific T cell expansion is 
context dependent. (A) Splenocytes isolated from a naive C57BL/6 mice were 
treated in vitro with anti-IFNαR1 mAb or IgG control (2.5 µg mAb) for 30 min and 
stimulated with recombinant IFN-α (2000 U/ml) for 1 h 45 min. The cells then fixed 
and p-STAT1 expression in CD4 T cells was determined by flow cytometry. Left, 
overlay of histograms representing p-STAT1 in CD4 T cells from IgG (MFI: 600) and 
anti-IFNαR1 treated (MFI: 198) splenocytes and Right, overlay of isotype stained CD4 
T cells from IgG (MFI: 159) and anti-IFNαR1 treated (MFI: 169) splenocytes. (B) Left, 
after transfer of Ag-specific T cells recipient mice were treated the next day with anti-
IFNαR1 mAb or IgG control and immunized with Eα+LPS+anti-CD134. On day 5 IFN-
β expression in the liver was quantified by qRT-PCR. The data is representative of 4 
independent studies with p value, *** < 0.001. Right, 3 h after immunization serum 
IFN-β was determined by ELISA, representative of 5 independent experiments with p 
value, **** < 0.0001. (C) Another group of mice treated as in 3-2B were analyzed for 
the; Left, percent and Right, total cell number of CD4+ Vα2+ Vβ6+ T cells in pLN and 
liver by flow cytometry. The data is representative of 4 independent experiments with 
p value, ** < 0.01. (D) Ag-specific T cells were transferred into WT and IFNαR-/- mice 
that were immunized with Eα+LPS+anti-CD134. On day 5, the percent of CD4 T cells 
expressing TCR Vα2+ Vβ6+ from pLN, liver and lung were quantitated by flow 
cytometry. The data is representative of 2-3 independent experiments with p value, * 
< 0.05. Error bars represent SEM of all experiments in that group. 
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Figure 3-3. Absence of IFNαR signaling in specific T cells handicaps their expansion.     
(A) CD4 T cells isolated from CD45.1+ WT mice and CD45.2+ IFNαR-/- mice were mixed at 
approximately a 1:1 ratio to generate an equal percentage of CD45.1+ (WT) and CD45.1- 
(IFNαR-/-) T cells before transferring them into TCR βδ-/- recipients. The next day mice were 
i.p. Immunized with SEA, LPS and anti-CD134, and on days 7 or 8 (B) and 15 (C) the cells 
isolated from pLN (Top) and the liver (Bottom) were analyzed for the percent Vb3+ CD45.1+ 
(WT) and Vb3+ CD45.1- (IFNaR-/-) T cells by flow cytometry. The data is presented as average 
of percent WT (Vb3+ CD45.1+) and IFNαR-/- (Vb3+ CD45.1-) T cells from all TCR βδ-/- mice 
where the connecting lines represent the WT and IFNαR-/- T cells in an individual mouse. The 
data is representative of 4 independent studies with p value, ** < 0.01, *** < 0.05, **** < 0.001. 
Error bars represent SEM of all experiments in that group.  
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Figure 3-4. IFNαR signaling in non-specific cells of the host promotes IFN-
γ production from specific as well as non-specific CD4 T cells. A. Mice treated 
in Fig. 3-2C, were used to analyze the percent (upper panels) and total number 
(lower panels) of IFN-γ expressing specific (Vα2+ Vβ6+) and non-specific (Vα2- Vβ6-) 
CD4 T, in pLN after with Eα peptide or PMA+Ionomycin stimulation. B. Mice treated 
as in Fig. 3-2D were used to analyze the percent of IFN-γ expressing specific (left 
panels) and non-specific (right panels) CD4 T cells in pLN, liver and lung after Eα 
peptide or PMA+Ionomycin stimulation. The data is representative of 2-3 
independent experiments with p value, * < 0.05, ** < 0.01, *** < 0.001. Error bars 
represent SEM of all experiments in that group.  
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Figure 3-5. IFNαR signaling enhances the accumulation of CXCR3 expressing 
specific as well as non-specific CD4 T cells in pLN.  Mice treated in Fig 3-2C, were 
used to calculate the percent and total number of CXCR3+ specific (Va2+ Vb6+) and non-
specific (Va2- Vb6-) CD4 T cells in pLN. The data is representative of 4 independent 
experiments with p value,  * < 0.05, ** <0.01, *** < 0.001. Error bars represent SEM of all 
experiments in that group  
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Figure 3-6	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Figure 3-6. CXCL9 and CXCL10 promotes the migration of Ag-specific T cells in 
the absence of Type I IFN signaling. After transfer of Ag-specific T cells, the next day 
recipient mice were treated with anti-IFNαR1 or IgG control and immunized with 
Eα+LPS+anti-CD134 and tested for migration potential (A). On days 5 (B) and 11 (C) 
cells were harvested from the pLN, suspended in CTM and added into the transwell 
inserts. The bottom of the well was filled with CTM alone or with CXCL9, CXCL10 or 
CXCL1. At 30 min the cells on top versus bottom were stained and analyzed for the 
percent of CD4 T cells expressing TCR Vα2+ Vβ6+. The graph shows the ratio of the 
percent of CD4 T cells expressing TCR Vα2+ Vβ6+ in the bottom versus the top.	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Figure 3-7. LPS induced Type I IFN signaling promotes the expression of 
chemokine CXCL9 and CXCL10. (A) The mice were treated as in Fig. 3-2C and liver 
tissue was harvested from the anti-IFNαR1 or IgG treated mice on day 2 (Top) and day 
5 (Bottom) and CXCL9 (Left) and CXCL10 (Right) mRNA expression were analyzed by 
qRT-PCR. The gene expression is normalized to β-actin and represented as fold 
change of IgG treated over anti-IFNαR1. The data is representative of 3-4 studies with 
p value, **** < 0.0001; ** < 0.01. (B) CXCL9 protein expression in liver of IgG and anti-
IFNαR1 treated mice was analyzed by immunoblot. Data represents 1 of 3 independent 
experiments, with 3 mice/group. (C) TEa cells were transferred into WT or IFNαR1-/- 
mice that were immunized with Eα+LPS+anti-CD134 (as in Fig. 3-2D) and 3 h later 
serum was collected followed by ELISA analysis of IFN-β, CXCL9 and CXCL10. The 
data is pooled from 3 independent experiments with p value, * < 0.05, ** < 0.01, **** < 
0.0001. (D) Left, TEa recipient WT or TRIF-deficient mice were i.p. Immunized and 3 h 
later CXCL9 serum levels were determined by ELISA. The data is representative of 4 
independent experiments with p value, **** < 0.0001. Right, The CXCL9 serum levels 
from the mice in Fig. 1 were analyzed by ELISA. The data is pooled from 2-3 
experiments. Error bars represent SEM of all experiments in that group. 
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Figure 3-8. CXCL9 chemokine blockade interferes with Ag-specific T cell 
accumulation. (A) Recipient WT mice were immunized (Eα+LPS+anti-CD134) the 
next day together with anti-CXCL9 or IgG control, and 8 h later anti-CXCL9 or IgG 
control was administered again. On day 6, the percent of CD4 T cells expressing TCR 
Vα2+ Vβ6+ in pLN, liver and lung were analyzed by flow cytometry. The data is 
representative of 3 independent studies with p value, ** < 0.01. (B) Mice treated as in 
Fig. 3-8A were used to calculate the percent and total CXCR3 expressing 
(represented as 1x106) Ag-specific (Va2+ Vb6+ TEa) CD4 T cells in pLN. The data is 
representative of 3 independent experiments with p value, * < 0.05. Error bars 
represent the SEM of all experiments in that group. (C) Left, The serum levels of IFN-β 
and Right, CXCL9 were determined by ELISA in 3 h (after immunization) serum from 
the mice in Fig. 3-8A. The data is representative of 4 independent experiments with p 
value, ***** < 0.0001. Error bars represent SEM of all experiments in that group. 	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Gene  Accession No 
 
Forward Primer 
 
Reverse Primer 
 
PMID 
IFNβ NM_010510.1 5’-AGCTCCAAGAAAGGACGAACA-3’ 5’-GCCCTGTAGGTGAGGTTGAT-3’ 
25822250; 
24014881 
CXCL9 NM_008599.4 5’-GGAGTTCGAGGAACCCTAGTG-3’ 5’-GGGATTTGTAGTGGATCGTGC -3’ 23520491 
CXCL10 NM_021274.2 5’-CCAAGTGCTGCCGTCATTTTC -3’ 5’-GGCTCGCAGGGATGATTTCAA-3’ 22577359 
β-Actin NM_007393.3 5’-AAGGCCAACCGTGAAAAGAT-3’ 5’-GTGGTACGACCAGAGGCATAC-3’ 22981535; 
23520491 
PMID: PubMed reference 
number 
Table 1. Oligonucleotide primers used for real-time RT-PCR 
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Tissue WT IFNαR-/- 
pLN      1.98 ± 0.076 0.82 ± 0.029 
Liver    1.48 ± 0.021 ** 0.72 ± 0.010 
Lung    0.60 ± 0.009 ** 0.26 ± 0.006 
Table 2. IFNαR signaling impacts the accumulation of total 
number of Ag-specific T cells.
§
  
§
The mice from Fig. 3-2D were used to calculate the total number 
of Vα2
+ 
Vβ6
+ 
T cells (represented as x10
5
 cells) in pLN, liver and 
lung on day 5. The data is representative of 2-3 independent 
experiments with p value, ** < 0.01, represented as Mean ± 
SEM, analyzed using students unpaired t test. 
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pLN 
(Vβ3
+
 T cells) 
WT IFNαR-/- 
Day 7   0.2292 ± 0.083 * 0.02816 ± 0.008 
Day 15       0.1128 ± 0.057 0.02497 ± 0.012 
Liver 
(Vβ3
+
 T cells) 
WT IFNαR-/- 
Day 7 0.3953 ± 0.094 ** 0.07573 ± 0.014 
Day 15 0.7306 ± 0.147 ** 0.1675 ± 0.034 
§ 
Mice from Fig 3-3B/C were used to calculate total number of 
Vβ3
+
 CD45.1
+
 (WT) and Vβ3
+
 CD45.1
-
 T (IFNαR
-/- 
) cells in each 
mouse. The table represents mean total number of SEA-specific 
WT and IFNαR
-/- 
T cells from 3-4 mice per group from 4 
independent experiments. p value, * < 0.05 and ** < 0.01,  
represented as Mean ± SEM using students unpaired t test. 
 
Table 3. IFNαR signaling in T cells impacts the total number of 
SEA-specific T cells.
§
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   IgG	   anti-CXCL9	  
pLN	  
 
    0.089 ± 0.0098 ** 
 
0.048 ± 0.0083 
Liver	  
 
0.090 ± 0.0158 
	  
 
0.061 ± 0.0105 
	  
Lung 0.065 ± 0.0081 0.046 ± 0.0077 
Table 4. Chemokine CXCL9 impacts the total number of Ag-
specific T cells in the pLN.
§
  
§ 
The mice from Fig. 3-8A were used to calculate the total 
number of Vα2
+ 
Vβ6
+ 
TEa cells (represented as x10
6
 cells) in 
pLN, liver and lung on day 6. The data is representative of 3 
independent experiments with p value ** < 0.01, represented 
as Mean ± SEM using students unpaired t test. 
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CHAPTER IV: 
Combining Poly I:C with CD134 agonist promotes enhanced CD4 T cell expansion and 
Th1 differentiation that is dependent on type I IFN signaling 
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Abstract 
Poly I:C is known to enhance both Th1 and CD8 T cell response, which makes it an ideal 
adjuvant in vaccines. Several reports have suggested that poly I:C mediates its adjuvant effect 
on CD4 T cells through induction of IFNαR signaling. Interestingly a recent study 
demonstrated, in a vaccine combining poly I:C with CD40 agonist that the enhanced CD4 T 
cell expansion and Th1 differentiation in response to this vaccine, relies on the CD134L 
expression on DC’s. This suggested to us, that poly I:C could enhance the CD4 T cell 
response in poly I:C/anti-CD40 vaccine by indirectly triggering the CD134 costimulation. We 
therefore investigated, if poly I:C can be directly combined with CD134 costimulation to 
promote enhanced Ag-specific CD4 T cell expansion and Th1 differentiation. We show that, 
combining Eα peptide with poly I:C and anti-CD134, promotes maximal Ag-specific CD4 T cell 
expansion and Th1 differentiation in comparison to peptide administered with poly I:C or anti-
CD134 alone. Importantly, the enhanced T cell expansion and Th1 differentiation observed 
during poly I:C and anti-CD134 immunization was dependent on IFNαR signaling. Moreover, 
combining poly I:C with anti-CD134 promoted enhanced generation of effector memory CD4 T 
cells during a recall response and it was also dependent on IFNαR signaling. Thus, the ability 
of poly I:C and anti-CD134 to promote the generation of long-lived effector CD4 T cells, could 
be utilized in development of vaccines against diseases where Th1 responses are crucial. 
However, the more novel observation was that CD134 costimulation induced specific CD4 T 
cell expansion and Th1 differentiation also relied on IFNαR signaling. It is not known how 
CD134 costimulation triggers IFNαR signaling to promote effector CD4 response. 
Understanding the mechanism behind it is important for efficient targeting of CD134 in 
preclinical cancer trials. 
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Introduction 
Several TLR agonists are currently being evaluated for their potential in inducing a potent CD4 
Th1 response that is important in resistance to global infectious diseases such HIV, 
tuberculosis, and malaria. Among them, synthetic dsRNA, poly I:C is known to be a superior 
adjuvant in comparison to other TLR adjuvants in mediating enhanced CD4 T cell immunity to 
protein antigens [21, 22, 66]. Poly I:C, binds to endosomal TLR3 or cytosolic receptor MDA5 to 
induce strong interferon production [53-55, 308]. Poly I:C induced interferon has shown to 
promote the generation of multifunctional CD4 T cells with ability to induce high levels of IL-2, 
IFN-γ and TNF-α [21-23, 66].  
Poly I:C and its derivative, Poly I:CLC, have been shown to enhance CD4 T cell and antibody 
immunity in vaccines against HIV, malaria, HPV [21, 23, 66, 69, 70], whereas Poly I:C12U, is 
currently been investigated in certain cancers for its role in DC maturation, IL-12 induction and 
ability to enhance Th1-type and CTL responses [64, 65]. Notably, a few studies showed that 
combining poly I:C with costimulatory agonist CD40 further enhances the Ag-specific CD4 T 
cell expansion and Th1 differentiation [201, 202, 205, 206]. Following on this, subsequent 
studies demonstrated that, poly I:C and anti-CD40 mediated enhanced CD4 T response was 
dependent on IFNαR signaling induced OX40L/CD134L expression on DC’s [27]. We 
therefore, decided to study if poly I:C can synergize with CD134 agonist directly to promote 
enhanced CD4 Th1-type immunity. Our results demonstrate that, administration of Eα peptide 
with poly I:C and anti-CD134 promotes maximal specific CD4 T cell expansion and Th1 
differentiation than peptide administered with poly I:C and anti-CD134 alone. The enhanced 
CD4 T cell response induced by combining poly I:C with anti-CD134 was dependent on IFNαR 
signaling, as the specific CD4 T cell expansion and Th1 differentiation were significantly 
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reduced in in mice treated with anti-IFNαR1 mAb.  
More importantly we observed that, CD134 costimulation induced CD4 T cell expansion and 
Th1 differentiation was also dependent on IFNαR signaling. The role of CD134 costimulation 
requiring IFNαR signaling to promote CD4 response is unknown. Is it important to identify the 
mechanism behind this in future, since CD134 is targeted in several advanced cancers to 
enhance the effector CD4 and CD8 T cell responses and promote anti-tumor immunity [248, 
251, 252, 257, 309].  
Finally, we also demonstrate that, combined administration of Eα peptide with poly I:C and 
anti-CD134 programs specific-CD4 T cells during early immune response to promote their 
development into optimal effector memory CD4 T cells after a secondary challenge. The 
enhanced generation of effector memory CD4 T cells was also dependent on IFNαR signaling 
induced during early immune response. Thus, the combination of Ag, poly I:C and anti-CD134 
should be explored in future for development of therapeutic vaccines against infectious 
diseases caused by intracellular bacteria and viruses, or in cancer where Th1 responses are 
crucial.  
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Results 
 
Combined administration of poly I:C and CD134 agonist promotes enhanced CD4 T cell 
expansion and Th1 differentiation that is dependent on type I IFN signaling.  
It was recently demonstrated that, poly I:C and CD40 agonist when combined together 
promotes enhanced CD4 T cell expansion and Th1 differentiation. This enhanced CD4 T cell 
response was dependent on IFNαR signaling induced CD134L expression on CD8+ DC’s [27]. 
Hence, we analyzed if poly I:C could be combined with CD134 costimulation directly to 
promote enhanced CD4 T cell response. For this we transferred ~ 1x106 Thy 1.1+ TEa cells to 
C57BL/6 mice, followed by their treatment with anti-IFNαR1 mAb or IgG control and 
immunization with Eα+poly I:C, Eα+anti-CD134 or Eα+poly I:C+anti-CD134. We first 
confirmed, if poly I:C induces type I IFN in our vaccine model. As shown in Fig. 4-1A, 
immunization with poly I:C, induced ∼180-200 pg/ml of type I IFN (IFN-β) in serum, during both 
Eα+poly I:C or Eα+poly I:C+anti-CD134 immunization, whereas administration of Eα+anti-
CD134 induced minimal levels of type I IFN (∼25-30 pg/ml). Furthermore IFNαR1 blockade 
significantly increased the IFN-β levels in the serum during Eα+poly I:C and Eα+poly I:C+anti-
CD134 immunization in comparison to control treated mice. This is likely due to unavailability 
of IFNαR1 to bind to IFN-β as seen previously with LPS and anti-CD134 vaccine. Overall, poly 
I:C induces significant levels of IFN-β and addition of anti-CD134 did not further influence 
it. Next we analyzed the expansion of Thy 1.1 cells on day 6 after immunization in mice treated 
as above and observed that both the percent (Fig. 4-1B, left panels) and total number of Thy 
1.1 cells (Fig. 4-1B, right panels) were maximal in the spleen and liver of mice immunized with 
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Eα, poly I:C and anti-CD134 in comparison to Eα administered with poly I:C or anti-CD134 
alone. In the liver, the expansion of Thy 1.1 cells were also enhanced with Eα and anti-CD134 
immunization, but the percent and total number of Thy 1.1 cells varied a lot between individual 
experiments (Fig. 4-1B, lower panels). Whereas, immunization with Eα, poly I:C and anti-
CD134 promoted consistent expansion of Thy 1.1 cells in liver, that were comparable between 
the experiments. Thus, combining poly I:C with anti-CD134 also promotes enhanced specific 
CD4 T cell expansion in the liver. Importantly, treatment with anti-IFNαR1 mAb significantly 
reduced the percent and total number of Thy 1.1 cells in spleen and liver during Eα, poly I:C 
and anti-CD134 immunization, suggesting that IFNαR signaling is essential for the enhanced T 
cell expansion induced by poly I:C and anti-CD134 combination.  
We next evaluated, if combined administration of Eα peptide, poly I:C and anti-CD134 can 
promote enhanced Th1 differentiation in Thy 1.1 cells. For this, we analyzed the intracellular 
secretion of IFN-γ and TNF-α in Thy 1.1 cells from experiment done in Fig 4-1B. Our results 
demonstrate that, combining Eα peptide with poly I:C and anti-CD134 increases the 
percentage of IFN-γ+, TNF-α+ and IFN-γ+ TNF-α+ Thy 1.1 cells in spleen after Eα peptide 
stimulation in comparison to Eα peptide given with poly I:C or anti-CD134 alone (Fig 4-2A, 
upper panels). The total numbers of IFN-γ+, TNF-α+ and IFN-γ+ TNF-α+ Thy 1.1 cells in spleen 
were also significantly increased with Eα, poly I:C and anti-CD134 immunization (data not 
shown). In liver, however, immunization with Eα and anti-CD134 promoted enhanced Th1 
differentiation in comparison to Eα+poly I:C or Eα+poly I:C+anti-CD134 combination as seen 
by the increased percentage of IFN-γ+, TNF-α+ and IFN-γ+ TNF-α+ Thy 1.1 cells after Eα 
peptide stimulation (Fig 4-2A, lower panels). Although, the percentage of IFN-γ+ and TNF-α+ 
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Thy 1.1 cells were enhanced with Eα and anti-CD134 immunization, the total number of IFN-
γ+, TNF-α+  and IFN-γ+ TNF-α+ Thy 1.1 cells were more significantly increased with Eα, poly 
I:C and anti-CD134 immunization (Fig. 4-2B), suggesting that this vaccine also promotes 
enhanced Th1 differentiation in the liver. We next evaluated if treatment with anti-IFNαR1 Ab 
impacts the Th1 differentiation induced by Eα, poly I:C and anti-CD134. As shown in the Fig 4-
2, upper panels, IFNαR1 blockade significantly reduced the percentage of IFN-γ+ Thy 1.1 
cells, whereas the percentage of TNF-α+ and IFN-γ+ TNF-α+ Thy 1.1 cells also trended towards 
reduction. Additionally, the total number of IFN-γ+, TNF-α+ and IFN-γ+ TNF-α+ Thy 1.1 cells 
were significantly reduced in spleen after anti-IFNαR1 treatment (not shown). In liver, IFNαR1 
blockade significantly reduced the percent of IFN-γ+ and TNF-α+ Thy 1.1 cells during Eα 
peptide and anti-CD134 immunization, whereas the percent of IFN-γ+ TNF-α+ Thy 1.1 cells also 
trended towards reduction (Fig 4-2, upper panels). The total number of IFN-γ+, TNF-α+ and 
IFN-γ+ TNF-α+ Thy 1.1 cells were however significantly reduced during Eα, poly I:C and anti-
CD134 immunization (Fig 4-2, lower panels).  
Overall this result suggests, that combining Ag with poly I:C and anti-CD134 promotes 
enhanced specific CD4 T cell expansion in both spleen and liver. Whereas, Th1 differentiation 
was mainly enhanced in the spleen, except the total number of Th1 type CD4 cells were 
increased in the liver with this vaccine. Importantly, IFNαR signaling was required for Th1 
differentiation during both Eα+anti-CD134 and Eα+poly I:C+anti-CD134 immunization. The 
role of CD134 costimulation relying on IFNαR signaling to promote effector CD4 T cell 
response is unknown and the mechanism behind it needs to be evaluated in future.  
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CD134 costimulation relies on type I IFN signaling to promote CD4 T cell expansion and 
Th1 differentiation.  
As the results above, suggested that CD134 costimulation requires IFNαR signaling to 
promote Th1 differentiation, we next analyzed if specific CD4 T cells activated with CD134 
agonist requires IFNαR signaling to induce Th1 differentiation. For this, we transferred ~1x106 
WT (Thy 1.1+ Thy 1.2+ TEa) or CD134-/- (Thy 1.1+ Thy 1.2- TEa+) CD4 T cells separately into 
C57BL/6 mice, followed by their treatment with anti-IFNαR1 Ab or control and immunization 
with Eα and anti-CD134. Our results in Fig. 4-3A show that, the percent and total number of 
specific CD4 T cells on day 8 after immunization were significantly increased in the spleen and 
liver of mice that received WT T cells, in comparison to CD134-/- T cells. The WT T cell 
expansion in the liver varied a lot between experiments after Eα peptide and anti-CD134 
immunization as seen previously in Fig. 4-1B. It is known that CD134 signaling in T cells 
enhances their expansion and survival [17, 212, 229], so this result was not surprising to us. 
More importantly, the treatment with anti-IFNαR1 mAb, resulted in significant reduction in the 
percentage (Fig. 4-3A, left panels), and the total number of specific WT T cells in spleen also 
trended towards reduction. In liver, anti-IFNαR1 treatment reduced the percent and total 
number of specific WT T cells, but it did not significantly do so (Fig. 4-3A, right panels). In mice 
that received CD134-/- T cells, IFNαR1 blockade had no further impact on specific T cell 
expansion. This data is, however, different from the results shown in Fig. 4-1B, where the 
percent and total number of specific WT T cells, were not significantly reduced in spleen during 
Eα peptide and anti-CD134 immunization after IFNαR1 blockade. This could be a result of 
IFNaR1 signaling impacting T cell survival during CD134 costimulation rather than expansion, 
as the data in Fig. 4-3 is analyzed on day 8 after expansion, in comparison to data in Fig 4.1, 
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which is representative of day 6 expansion. However, overall these results suggest that CD134 
costimulation relies on IFNαR signaling to promote specific CD4 T cell expansion. We also 
analyzed the IFN-β levels in serum of mice that received WT or CD134-/- T cells, followed by 
immunization. We saw in mice that received WT T cells, ~10 pg/ml of IFN-β were induced, 
which significantly increased in mice that received CD134-/- T cells (Fig. 4-3B). It could indicate 
that CD134 costimulation in activated T cells enhances IFNαR1 expression on them, and in 
mice that receives CD134-/- cells, the reduced IFNαR1 expression, results in increased IFN-β 
levels in the serum. However we haven’t analyzed this possibility. Also in mice, that received 
WT T cells followed by anti-IFNαR1 treatment, the IFN-β levels were significantly increased in 
comparison to control treated mice, which could be due to unavailability of IFNαR1 to bind IFN-
β. Whereas in mice that received CD134-/- T cells, IFNαR1 blockade has no further impact on 
IFN-β levels. Overall even though we saw statistically significant differences in type I IFN levels 
in mice that received WT versus CD134-/- T cells, we do not know if these differences are 
biologically significant. 
We next evaluated, if CD134 costimulation in specific T cells requires IFNαR signaling to 
promote Th1 differentiation. For this, we analyzed intracellular IFN-γ, TNF-α expression in 
specific T cells from experiment done in Fig 4-3A. Our results shown in Fig. 4-4 demonstrate 
that, the percentage of IFN-γ+, TNF-α+ and IFN-γ+ TNF-α+  specific WT CD4 T cells were 
substantial in spleen after Eα peptide (Fig. 4-4A) or PMA+Ionomycin (Fig. 4-4B) stimulation. In 
comparison, the percentage of IFN-γ+, TNF-α+ and IFN-γ+ TNF-α+  CD134-/- T cells were 
significantly reduced. The total number of IFN-γ+, TNF-α+ and IFN-γ+ TNF-α+  T cells were also 
significantly reduced in mice that received CD134-/- T cells (not shown).  These results are in 
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agreement with the previous reports that show the role of CD134 signaling in promoting Th1 
differentiation [17, 210, 239]. More importantly treatment with anti-IFNαR1 mAb significantly 
reduced the percent of IFN-γ+, TNF-α+, IFN-γ+ TNF-α+  specific WT T cells in spleen after 
Eα peptide (Fig. 4-4A) and PMA+Ionomycin (Fig. 4-4B) stimulation. The total number of IFN-γ+, 
TNF-α+, IFN-γ+ TNF-α+ specific WT T cells in spleen were significantly reduced after 
Eα peptide stimulation, whereas they trended towards reduction after PMA+Ionomycin 
stimulation, but did not reach significance (not shown). In liver, treatment with anti-IFNαR1 
mAb did not impact the percentage of IFN-γ+, TNF-α+, IFN-γ+ TNF-α+ specific WT T cells during 
Eα peptide stimulation (Fig. 4-4A). However, after PMA+Ionomycin stimulation the percentage 
(Fig. 4-4B) and total number of IFN-γ+ and IFN-γ+ TNF-α+ specific WT T cells (not shown) 
trended towards reduction. Finally, their was IFNαR1 blockade did not influence the Th1 
differentiation in on CD134-/- CD4 T cells (not shown).  
Overall, these result suggests that, CD134 signaling in specific CD4 T cells requires IFNαR 
signaling to promote optimal Th1 differentiation.  This is a novel observation and the 
mechanism of how, CD134 and IFNαR signaling work together to promote CD4 T cell 
expansion and Th1 differentiation, needs be explored in future studies. 
 
Combined administration of poly I:C and CD134 agonist promotes enhanced generation 
of effector memory CD4 T cells.  
Since combining poly I:C with CD134 agonist promoted enhanced CD4 T cell expansion and 
Th1 differentiation during primary immune response, we evaluated if this combination also 
promotes enhanced CD4 T cell expansion and cytokine differentiation during memory 
response. For this, we transferred ~ 1x106 cells Thy 1.1+ TEa cells into C57BL/6 mice, followed 
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by their treatment with anti-IFNαR1 Ab or control and immunization with Eα+poly I:C, Eα+anti-
CD134 and Eα+poly I:C+anti-CD134 as before. On day 30 or 31 mice were re-challenged with 
Eα and poly I:C and the specific memory CD4 T cells were analyzed in spleen and liver. As 
shown in the Fig. 4-5, immunization with Eα, poly I:C and anti-CD134 resulted in significant 
increase in percent and total number of specific memory CD4 T cells in spleen in comparison 
to Eα administered with poly I:C or anti-CD134 alone (Fig. 4-5, upper panels). Importantly, 
IFNαR1 blockade during early T cell priming reduced the percent of specific memory CD4 T 
cells in spleen, almost significantly, whereas, the total number of memory CD4 T cells, were 
significantly reduced (Fig. 4-5, upper panels). In liver, immunization with Eα, poly I:C and anti-
CD134 also promoted maximal expansion of specific memory CD4 T cells. However, unlike 
spleen, the expansion was not drastic and it did not significantly differ in comparison to the 
expansion induced with Eα and anti-CD134 immunization (Fig. 4-5, lower panels). 
Furthermore, IFNαR1 blockade did tend to reduce the percent and total number of specific 
memory CD4 T cells in liver, during Eα, poly I:C and CD134 immunization, however, they were 
not significantly impacted.  
Overall, this data suggests that, immunization with Ag, poly I:C and anti-CD134 programs the 
specific CD4 T cells in spleen during early phase of immune response to expand optimally 
after a secondary challenge. 
We next determined, if immunization with Eα, poly I:C and anti-CD134 promotes optimal Th1 
differentiation of specific CD4 T cells during the recall response. For this we analyzed the 
intracellular IFN-γ, TNF-α expression in specific CD4 T cells from experiment done in Fig. 4-5.  
As shown in Fig 4-6, immunization with Eα+poly I:C+anti-CD134 resulted in substantial 
increase in the percent of IFN-γ+, IFN-γ+ TNF-α+ specific memory CD4 T cells in spleen, after 
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Eα peptide (Fig. 4-6A) and PMA+Ionomycin stimulation (Fig. 4-6B). However, the percent of 
IFN-γ+ and TNF-α+ specific memory T cells were more significantly enhanced after 
PMA+Ionomycin stimulation, as there was a significant increase in percent of these cells with 
Eα+poly:IC+anti-CD134 in comparison to Eα+poly I:C and Eα+anti-CD134 immunization (Fig. 
4-6B, upper panels). Furthermore anti-IFNαR1 treatment significantly reduced the percent of 
IFN-γ+ and IFN-γ+ TNF-α+ specific memory CD4 T cells in spleen, not only during Eα+poly 
I:C+anti-CD134 immunization (after Eα peptide stimulation, Fig. 4-6A, upper panels) but also 
during Eα+poly I:C and Eα+anti-CD134 immunization (with PMA+Ionomycin stimulation, Fig. 
4-6B, upper panels). The total number of IFN-γ+ and IFN-γ+ TNF-α+ specific memory T cells in 
spleen, also followed similar trend where they expanded more with Eα+poly I:C+anti-CD134 
immunization in comparison to Eα given with poly I:C or anti-CD134 (not shown) and anti-
IFNαR1 treatment reduced the total number of IFN-γ+ and IFN-γ+ TNF-α+ memory T cells even 
though it didn’t reach significance (not shown).  In liver, immunization with Eα+poly:IC+anti-
CD134 increased the percent of IFN-γ+ specific memory T cells after Eα peptide stimulation 
(Fig. 4-6A, lower panels), but it was not significant in comparison to Eα administered with poly 
I:C or anti-CD134. However, with PMA+Ionomycin stimulation, Eα+ poly I:C+anti-CD134 
immunization increased the percent of IFN-γ+ and IFN-γ+ TNF-α+ specific memory T cells 
significantly in comparison to Eα+poly I:C or Eα+anti-CD134 immunization (Fig 4-6B, lower 
panels). Furthermore, IFNαR1 blockade significantly reduced the percent of IFN-γ+ specific 
memory T cells in liver after Eα peptide stimulation (Fig. 4-6A, lower panels), and the percent 
of IFN-γ+ and IFN-γ+ TNF-α+ specific memory T cells after PMA+Ionomycin stimulation (Fig. 4-
6B, lower panels). Finally, immunization with Eα+poly I:C+anti-CD134 also significantly 
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enhanced the Tbet expression (Th1 transcription factor Tbet, encoded by TBX21) on IFN-γ+ 
specific memory T cells in spleen during Eα peptide (Fig. 4-6A, upper right panel) and 
PMA+Ionomycin stimulation (Fig. 4-6B, upper right panel) and the enhanced Tbet expression 
was also dependent on IFNαR signaling. This suggests that IFNαR signaling induced with 
Eα+poly I:C+anti-CD134 immunization during early immune response promotes Th1 lineage 
commitment in specific CD4 T cells, by enhancing the expression of Tbet. 
Overall, these results highlights the importance of combining, Ag with poly I:C and CD134 
agonist to promote long-lasting Th1-type CD4 T cell immunity, and this combination should be 
evaluated for its efficacy in vaccines targeting infectious diseases or cancer, where Th1 
responses are crucial. 
We next evaluated, if our previous vaccine combining of Eα peptide, LPS and anti-CD134 
requires IFNαR signaling to promote the generation of effector memory CD4 T cells, similar to 
poly I:C and anti-CD134 combination. To analyze this, TEa or Thy 1.1 cells were transferred to 
C57BL/6 mice, followed by their treatment with anti-IFNαR1 Ab or control and immunization 
with Eα, LPS and anti-CD134. The mice were re-challenged with Eα peptide and LPS on day 
28 or 31, following which on day 5 or 7, the specific CD4 T cells were analyzed for expansion 
and cytokine secretion. As shown in Fig. 4-7A, IFNαR signaling induced by Eα+LPS+anti-
CD134 during early T cell priming, did not influence the expansion of specific memory CD4 T 
cells in pLN and liver, after a recall challenge. Furthermore, anti-IFNαR1 treatment did not 
impact the percent of IFN-γ+ and TNF-α+ specific memory CD4 T cells in pLN and liver after Eα 
peptide stimulation (Fig 4-7B) or PMA+Ionomycin stimulation (not shown). Rather, the IFNαR1 
blockade slightly enhanced the specific CD4 T cell expansion (Fig 4-7A) and Th1 
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differentiation (Fig 4-7B). Thus, even though the combination of peptide Ag, LPS and anti-
CD134 is known to promote optimal CD4 T cell memory [19], LPS induced IFNαR signaling 
does not play a role in this. Higher dependence of poly I:C on IFNαR signaling to promote 
effector memory CD4 T cell response could be a result of it activating both TLR3 and MDA-5 
signaling pathways, in comparison to LPS, which induces interferon only through TLR4-TRIF 
pathway. Therefore its possible that Eα, LPS and anti-CD134 induced memory CD4 T cell 
response is dependent on MyD88 signaling, as a result of which the absence of IFNαR 
signaling has no impact on the LPS induced memory CD4 T cell response. 
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Discussion 
 
Poly I:C and its derivatives have shown a great promise in promoting Th1-type immune 
response and therefore are used as adjuvants in vaccines against several infections diseases 
such as HIV, HPV and malaria [21, 23, 66, 69, 70]. Moreover its ability to impact a variety of 
immune cells, such as CD4 [21, 23, 59, 66] and CD8 T cells [58, 310, 311], NK cells [112, 312] 
and DC’s [22, 53, 57, 201] has compelled investigators to test its efficacy in cancer vaccines.  
Recently, few studies demonstrated that combining poly I:C with CD40 agonist promotes 
generation of multifunctional effector CD4 T and CD8 T cells that are able to protect against 
several viral infections (HIV, HCV, RSV) [201, 202, 204, 205, 313] and promote anti-tumor 
immunity in preclinical cancer models (cervical cancer, melanoma, lymphoma) [314-316]. Later 
studies, suggested that the enhanced effector T cell response induced by poly I:C and anti-
CD40 combination relied on CD134L expression on CD8+ DC’s [206], where IFNαR signaling 
enhanced the CD134L expression on DC’s [27]. Hence we analyzed, if poly I:C can be directly 
combined with CD134 costimulation to promote enhanced CD4 T cell expansion and Th1 
differentiation. Our results show that, combining peptide Ag with poly I:C and anti-CD134, 
promotes maximal CD4 T cell expansion and Th1 differentiation in lymphoid (spleen) and non-
lymphoid tissue (liver) in comparison to Ag administered with poly I:C or anti-CD134 (Fig 4-
1B). Furthermore, we saw that poly I:C and anti-CD134 combination enhanced the percentage 
(Fig 4-2A, upper panel) and total number (not shown) of Th1-type specific CD4 T cells in 
spleen after Eα peptide stimulation. Whereas, in the liver, immunization with Eα and anti-
CD134 also increased the percentage of Th1-type CD4 T cells (Fig. 4-2A, lower panel) and Eα 
and anti-CD134 induced Th1 differentiation relied on IFNαR signaling (Fig. 4-2A). However, 
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the total number of Th1-type CD4 cells, were more significantly increased with Eα+poly 
I:C+anti-CD134 immunization (Fig. 4-2B). Importantly, similar to poly I:C and anti-CD40 
combination, poly I:C and anti-CD134 induced Th1 differentiation in spleen also relied on 
IFNαR signaling (Fig 4-2A, upper panel). 
The primary source of type I IFN in our vaccine model is poly I:C, whereas anti-CD134 
stimulation induced minimal levels of type I IFN (Fig 4-1A). The high molecular weight poly I:C 
used in our study could trigger type I IFN through both TLR3 and MDA5 pathways. Previous 
study from our lab demonstrated that, poly I:C induced effector CD8 T cell expansion during an 
acute response was independent on TLR3 signaling, whereas generation of effector memory 
CD8 T cells required TLR3 signaling [311]. In line with this, poly I:C induced long-term effector 
CD4 cell response to a DC-targeted HIV-gag vaccine was shown to be dependent on both 
TLR3 and MDA-5 pathways [21, 22]. Understanding, which signaling pathway is triggered 
during poly I:C and anti-CD134 immunization, could help evaluate the mechanism of how this 
combination enhances effector CD4 T cell response. 
In sum, results above suggest that combining Ag with poly I:C and CD134 agonist promotes 
enhanced CD4 T cell expansion and Th1 differentiation. Therefore, this combination should be 
evaluated for its effectiveness in therapeutic vaccines against infectious disease or tumor 
models where Th1 responses are crucial.  
As, immunization with Eα and anti-CD134 relied on IFNαR signaling to promote optimal Th1 
differentiation in liver (Fig 4-2A, lower panel), we further evaluated, if CD134 costimulation in T 
cells requires IFNαR signaling to promote Th1 differentiation. Our results show that specific 
WT CD4 T cells expanded significantly more in comparison to CD134-/- T cells in spleen during 
Eα and anti-CD134 immunization and this expansion was dependent on IFNαR signaling (Fig. 
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4-3A). In liver, WT T cell expansion varied a lot between the experiments, but it was still 
dependent on IFNαR signaling. Furthermore, WT T cells stimulated with Eα and anti-CD134 
induced optimal Th1 differentiation after Eα peptide (in spleen, Fig. 4-4A, upper panel) and 
PMA+Ionomycin (in spleen and liver, Fig. 4-4B) stimulation in comparison to CD134-/- T cells. 
Importantly, the CD134 costimulation induced Th1 differentiation in WT CD4 T cells of spleen, 
required IFNαR signaling (Fig. 4-4A/B). Thus even though administration of Ag with CD134 
agonist induced minimal levels of type I IFN (IFN-β) (Fig. 4-3B), it was somehow sufficient to 
promote specific CD4 T cell expansion and Th1 differentiation.  
Antibodies targeting CD134 are currently used in several preclinical cancer trials to promote 
generation of tumor specific CD4 and CD8 T cells with optimal effector function [18, 244, 248, 
257, 309]. Therefore, understanding how CD134 agonist triggers interferon induction to 
promote CD4 T cell expansion and Th1 differentiation is necessary for further use of the 
therapeutics targeting CD134.  
Finally, as combining poly I:C and anti-CD134 promoted enhanced CD4 T cell expansion and 
Th1 differentiation during primary immune response, we analyzed if this combination could 
promote enhanced generation of effector memory CD4 T cells during a recall response. Our 
results in Fig. 4-5A show that, immunization with Eα, poly I:C and anti-CD134 resulted in 
substantial increase in the percent and total number of specific memory CD4 T cells in spleen 
in comparison to Eα administered with poly I:C or anti-CD134 (Fig. 4-5A, upper panel). 
Whereas, in liver, Eα+poly I:C+anti-CD134 immunization significantly enhanced the specific 
CD4 T cell expansion in comparison to Eα and poly I:C, but not in comparison to Eα and anti-
CD134 immunization (Fig. 4-5A, lower panel). Importantly, the absence of IFNαR signaling 
during Eα+poly I:C+anti-CD134 caused significant reduction in total number of specific 
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memory CD4 T cells in spleen, whereas in liver, the total number of memory CD4 T cells were 
reduced, but were not significantly impacted. Overall, immunization with Ag, poly I:C and anti-
CD134 promotes enhanced generation of specific memory CD4 T cells during a recall 
challenge and it is dependent on IFNαR signaling induced early during the immune response. 
Moreover, immunization with Eα, poly I:C and anti-CD134 also promoted enhanced Th1 
differentiation of specific CD4 T cells in spleen after a recall challenge (Fig. 4-6A, upper panel). 
In liver, the total number of specific CD4 T cells after Eα+poly I:C+anti-CD134 immunization 
were less in comparison to spleen (not shown), therefore Eα peptide stimulation did not 
activate the CD4 T cells enough (Fig. 4-6A, lower panel). However, after PMA+Ionomycin 
stimulation the Th1 differentiation of specific CD4 T cells was enhanced in liver with Eα+poly 
I:C+anti-CD134 immunization (Fig. 4-6B, lower panel). Importantly the enhanced Th1 
differentiation seen in spleen and liver after Eα+poly:IC+anti-CD134 immunization was 
dependent on IFNαR signaling induced early during T cell priming (Fig. 4-6A/B). Additionally, 
immunization with Eα, poly I:C and anti-CD134 also enhanced the Tbet expression on IFN-γ+ 
specific CD4 T cells in spleen after Eα peptide and PMA+Ionomycin stimulation (Fig 4-6A/B, 
upper right panel), however it did not impact Tbet expression in liver (not shown). The 
enhanced Tbet expression on IFN-γ+ specific CD4 T cells (in spleen) was also dependent on 
IFNαR signaling. Tbet is known to regulate IFN-γ production by binding to the IFN-γ gene and 
up regulating the IL-12Rβ2 expression [317, 318]. Thus, immunization with Eα+poly I:C+anti-
CD134 seems to promote the Th1 lineage commitment in specific CD4 T cells through type I 
IFN, mediated induction of Tbet.  
Above mentioned results, are similar to a study published this year by Esteban Celis group, 
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where authors show, that adding anti-CD134 mAb to trivax vaccine (that combines peptide Ag, 
with poly I:C and anti-CD40) during a prime and boost immunization promotes the generation 
of long-lasting effector CD4 T cells [315]. However, their data shows that addition of anti-
CD134 to Trivax, does not enhance the effector CD4 T cell response on day 7, in comparison 
to Trivax given alone, whereas in our model, adding anti-CD134 to poly I:C, enhances the 
effector CD4 T response during early immune response (day 6) as well. It is possible that the 
addition of anti-CD134 to poly I:C and anti-CD40 does not impact early CD4 T cell response 
differently than poly I:C and anti-CD40 combination, but rather enhances the effector CD4 T 
cell response after a prime and boost immunization. Thus, it is important to compare CD4 T 
cell response induced by poly I:C and anti-CD134 and poly I:C, anti-CD134 and anti-CD40 
combination in the same experiment to see which combination is better at promoting short-
term and long term CD4 T cell response. Moreover, their results do not show that Ag+poly 
I:C+anti-CD40+anti-CD134 induced CD4 T cell response was dependent on IFNαR signaling; 
they rather showed using gardiquimod, GDQ (TLR7 agonist) that Ag+GDQ+anti-CD40+anti-
CD134 mediated effector CD4 T cell response was dependent on IFNαR signaling. Overall, 
our results show that combining poly I:C with CD134 agonist promotes enhanced generation of 
Th1-type CD4 T cells during both primary and memory phase of immune response. 
Additionally, the observation that CD134 costimulation requires IFNαR signaling to promote 
CD4 T cell expansion and Th1 differentiation is important and the mechanism behind this 
needs to be evaluated in the future studies. 
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Figure 4-1. Administration of Ag together with poly I:C and anti-CD134 promotes 
maximal expansion of specific CD4 T cells. About 1x106 of TEa+ Thy 1.1+ cells were 
transferred into C57BL/6 mice. Next day mice were treated with anti-IFNαR1 mAb or 
control, followed by immunization with Eα+poly I:C, Eα+anti-CD134 or Eα+poly I:C+anti-
CD134. A. The data represents the Elisa analysis of IFN-β levels in serum at 3 hr from 
mice treated as above. B. The graph depicts the percent and total number of Thy 1.1 
cells in spleen and liver of mice on day 6 after immunization. Data is representative of 3 
independent experiments with p value, * < 0.05, ** < 0.01. Error bars represent SEM of 
all experiments in that group. 
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Figure 4-2. Administration of Ag together with poly I:C and anti-CD134 
promotes enhanced Th1 differentiation of specific CD4 T cells. Mice treated as in 
Fig. 4-2 were analyzed for the percent and total number of IFN-γ+, TNF-α+ and IFN-
γ+TNF-α+ expressing Thy 1.1 cells in spleen and liver after in vitro stimulation with Eα 
peptide. Data is representative of 3 independent experiments with p value, * < 0.05, 
** < 0.01. Error bars represent SEM of all experiments in that group. 
, represented as mean ± SEM 
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Figure 4-3. CD134 costimulation requires IFNαR signaling to promote specific CD4 
T cell expansion. About 1x106 WT or CD134-/- Thy 1.1 TEa cells were seperately 
transfered into C57Bl/6 mice followed by treatment with anti-IFNαR1 mAb or IgG control 
and immunization with Eα peptide and anti-CD134. The data represents A. The percent 
and total number of WT (TEa+ Thy 1.1+ Thy 1.2+) and CD134-/- (TEa+ Thy 1.1+ Thy 1.2-) 
cells in the spleen and liver of mice on day 8 following immunization. B. Elisa analysis of 
IFN-β levels in serum, 3 h after immunization in mice treated as above. The data is 
representative of 4 independent experiments with p value, * < 0.05, ** < 0.01, *** < 
0.001. Error bars represent SEM of all experiments in that group. 
 
	  
Figure 4-3	  
%
 T
hy
 c
el
ls
 
WT CD134-/- 
Ig
G
 
an
ti-
IF
N
α
R
1 
Ig
G
 
an
ti-
IF
N
α
R
1 
WT
 - I
gG
WT
 - α
-IF
NA
R1
OX
40
-/- - 
IgG
OX
40
-/-  - 
α-I
FN
AR
1
0
1
2
3
4
5
%
 T
hy
+  c
el
ls
Spleen % WT and OX40ko in C57Bl6
**
**
ns
ns
Spleen Liver A 
WT CD134-/- 
Ig
G
 
an
ti-
IF
N
α
R
1 
Ig
G
 
an
ti-
IF
N
α
R
1 
WT
 - I
gG
WT
 - α
-IF
NA
R1
OX
40
-/- - I
gG
OX
40
-/-  -
 α-
IFN
AR
1
0.0
0.1
0.2
0.3
0.4
To
ta
l T
hy
+ 
(1
06
)
Spleen Total WT or OX40ko in C57Bl6
WT - IgG
OX40-/- - α-IFNAR1
OX40-/-- IgG
ns
1"x"106"
*
**
WT - α-IFNAR1
0.0559
WT
 - I
gG
WT
 - α
-IF
NA
R1
OX
40
-/- - I
gG
OX
40
-/-  -
 α-
IFN
AR
1
0.00
0.03
0.06
0.09
0.12
0.15
To
ta
l T
hy
 (1
06
)
Liver Total WT or OX40ko in C57Bl6 1x106
WT - IgG
OX40-/-- IgG
OX40-/- - α-IFNAR1
ns
1"x"106"
ns
ns
ns
WT - α-IFNAR1
Th
y 
ce
lls
 (1
06
) WT -
 Ig
G
WT
 - α
-IF
NA
R1
OX
40
-/- - I
gG
OX
40
-/-  -
 α-
IFN
AR
1
0
3
6
9
12
15
18
%
 T
hy
+ 
ce
lls
Liver % WT or OX40ko in C57Bl6 1x106
WT - IgG
WT - α-IFNAR1
OX40-/- - α-IFNAR1
1"x"106"
*
OX40-/-- IgG
0.0643
ns
ns
WT
 T 
ce
lls
 - I
gG
WT
 T 
ce
lls
 - α
IFN
AR
1
OX
40
-/-  T
 ce
lls
 - I
gG
OX
40
-/-  T
 ce
lls
 - α
IFN
AR
1
0
5
10
15
20
25
IF
N
-β
 (p
g/
m
l)
3 hr serum
WT T cells - IgG
OX40-/- T cells - IgG
OX40-/- T cells - αIFNAR1
*
*
ns
WT T cells - αIFNAR1
***
IF
N
-β
 (
pg
/m
l)
 
WT CD134-/- 
Ig
G
 
an
ti-
IF
N
α
R
1 
Ig
G
 
an
ti-
IF
N
α
R
1 
B 3 h serum 
	  108	  
	  
 
  
 
 
  
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-4	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Figure 4-4. CD134 costimulation requires IFNαR signaling to promote optimal Th1 
differentiation. Mice treated in Fig 4-3, were analyzed for the percent of IFN-γ+, TNF-
α+, IFN-γ+ TNF-α+ expressing WT and CD134-/- Thy 1.1 cells in spleen and liver after in 
vitro stimulation with A. Eα peptide and B. PMA+Ionomycin The data is representative 
of 4 independent experiments with p value, * < 0.05, ** < 0.01, *** < 0.001, *** < 0.0001. 
Error bars represent SEM of all experiments in that group. 
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Figure 4-5. Administration of Ag with poly I:C and anti-CD134 promotes maximal 
expansion of specific CD4 T cells during memory response. About 1x106 Thy 1.1 
TEa cells were transferred into C57BL/6 mice followed by their treatment with anti-
IFNαR1 mAb or IgG control and immunization with Eα+poly I:C, Eα+anti-CD134 or 
Eα+poly I:C+anti-CD134. Mice were re-challenged on day 30 or 31 with Eα+ poly I:C, 
following which the percent (left panel) and total number of Thy 1.1 cells (x106) (right 
panel) were analyzed on day 6 in spleen and liver. The data is representative of 2 
independent experiments with p value, * < 0.05. Error bars represent SEM of all 
experiments in that group.	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Figure 4-6	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Figure 4-6. Administration of Ag with poly I:C and anti-CD134 promotes enhanced 
Th1 differentiation of specific T cells during memory response. Mice treated in Fig. 4-
5 were analyzed for the percent and total number of IFN-γ+, TNF-α+ and IFN-γ+ TNF-α+ 
expressing Thy 1.1 cells in spleen and liver after in vitro stimulation with A. Eα peptide and 
B. PMA+Ionomycin stimulation. The data is representative of 4 independent experiments 
with p value, * < 0.05, ** < 0.01, *** < 0.001, *** < 0.0001. Error bars represent SEM of all 
experiments in that group. 
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Figure 4-7	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Figure 4-7. LPS induced IFNαR signaling is not required for specific CD4 T cell 
expansion and Th1 differentiation during memory response. Mice were treated 
as in Fig. 3-2, briefly ~1 x105 CD4 TEa or Thy 1.1 cells were transferred into C57BL/6 
mice followed by their treatment with anti-IFNαR1 mAb or control and immunization 
with Eα peptide, LPS and anti-CD134 mAb. On day 28 to day 31, mice were re-
challenged with Eα peptide and LPS, following which on day 5 or 7, memory CD4 T 
cells in pLN and liver were analyzed for A. Percent and total number (x106) of TEa or 
Thy 1.1 CD4 T cells. Black colored circles represent TEa cells whereas blue colored 
circles represent Thy 1.1 cells. B. Percent of IFN-γ+ and TNF-α+ expressing TEa cells 
after in vitro stimulation with Eα peptide. Data is representative of 5-6 individual 
experiments, where error bars represent SEM of all experiments in that group.	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Chapter V: DISCUSSION AND FUTURE DIRECTIONS 
 
(I) Understanding role of LPS induced signaling pathways in promoting optimal CD4 T 
cell immunity 
There are still no fully effective vaccines against many widespread infectious diseases, such 
as HIV, tuberculosis, and malaria. Although, humoral immunity has an important role in 
protecting against HIV infection [319] and influences certain stages of malaria infection [320], 
CD4-Th1 and CD8 T cell immunity also play a critical role in controlling these infections [321-
323]. Moreover, accumulating evidence suggests that vaccines targeting CD4 T cells can be 
effective in generating potent anti-tumor responses [324-327]. In line with this, there have been 
major advances in the last decade in development of adjuvants, which enhance the magnitude 
of T cell response in a vaccine. However, much less work is done in understanding how these 
adjuvants work at molecular level and how signaling mechanisms induced by these adjuvants 
enhance the CD4, Th1 response. Therefore, our aim is to understand how adjuvants, LPS and 
poly I:C induced responses impact the CD4 T cell expansion and Th1 differentiation. 
LPS, is a potent Th1 response inducing adjuvant, and injecting it systemically within a day after 
antigen exposure increases the level of T cell clonal expansion, long-term survival and T cell 
migration to the non-lymphoid tissues [328]. Even though MPL and not LPS, is used in 
approved human vaccines against HPV and HBV [14], due to its reduced toxicity, we decided 
to use LPS for few reasons (1) It promotes lasting CD4 T cell responses over MPL, which 
enhances short term CD4 T cell response [15] (2) To understand, if LPS induced IFNαR 
signaling could explain how LPS and anti-CD134 combination promotes enhanced CD4 T cell 
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expansion, survival and memory. (3) To analyze, if LPS-TRIF induced CD4 T cell migration 
and Th1 differentiation in non-lymphoid tissues of liver and lung, depends on downstream 
induction of type I IFN. 
 
(II) LPS induced IFNαR signaling in both specific T cells and non-specific cells 
contribute to CD4 T cell expansion and Th1 differentiation  
As mentioned above, one of our goals is to understand the mechanism of how LPS and 
CD134 agonist together promote enhanced CD4 T cell expansion and survival. Previous 
studies done in our lab have evaluated the role of different LPS induced pathways in 
enhancing the T cell response. LPS induced MyD88 pathway was shown to enhance T cell 
accumulation in both lymphoid and non-lymphoid tissues and much has been done in this area 
[11, 329]. Whereas, LPS induced TRIF signaling is known to promote initial T cell clonal 
expansion, up regulate the expression of costimulatory molecules on APCs and induce Th1 
differentiation in CD4 T cells [47, 277]. Subsequent studies in our lab showed the importance 
of TRIF signaling in promoting CD4 T cell accumulation to peripheral tissues of liver and lung 
[20], but the mechanism behind this is unknown. TRIF is known to induce type I interferon 
production [40], and type I IFN is known to directly act on T cells to enhance their expansion 
and survival [48, 133]. Therefore, we hypothesized that, LPS-TRIF induced type I interferon, 
could enhance the CD4 T cell expansion in the vaccine combination of LPS and CD134 
agonist. Our rationale behind this, was the enhanced production of type I IFN (IFN-β) (Fig. 3-
1B), seen during Eα peptide, LPS and anti-CD134 immunization, that corresponded with the 
synergistic T cell expansion this vaccine induced (Fig. 3-1C). Recently lipid A, included IFNαR 
signaling was shown to promote CD4 and CD8 T cell clonal expansion, during immunization 
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with lipid A and ovalbumin peptides (for MHC I and MHC II) [47]. However, they did not 
analyze if IFNαR signaling enhances CD4 T cell response in a vaccine model combining LPS 
and anti-CD134. They also did not evaluate the role of IFNαR signaling in promoting T cell 
expansion in tissues other than spleen.  
Our results show that depending on the model used, IFNαR signaling in both specific CD4 T 
cells and non-specific cells of the host impact the T cell expansion. Using a competition model, 
we saw that IFNαR signaling in specific T cells was required for their expansion in pLN and 
liver (Fig. 3-3). However, analyzing specific T cell expansion in IFNαR1-/- mice that received 
IFNαR sufficient T cells, suggested that IFNαR signaling in non-specific cells of the host also 
contribute to T cell expansion mainly in the liver and lung (Fig. 3-2D). Thus overall, IFNαR 
signaling in both specific T cells and non-specific cells promote CD4 T cell expansion. 
However, unlike the report mentioned above, where lipid A induced IFNαR signaling was 
required for T cell clonal expansion in spleen [47], we did not see a difference in CD4 T cell 
expansion in spleen. It is possible that additional inflammatory cytokines induced by LPS in 
comparison to lipid A, may support some level of T cell expansion in spleen after IFNαR 
blockade. Additionally, addition of CD134 agonist to LPS, may impact the type I interferon 
mediated T cell expansion differently in comparison to lipid A alone.  
In terms of Th1 differentiation, we saw that IFNαR signaling in non-specific cells of the host 
was predominantly required to promote Th1 differentiation from both specific and non-specific 
CD4 T cells, since IFN-γ production by specific T cells after Eα peptide stimulation, was 
significantly reduced in liver and also trended towards significant reduction in pLN of IFNαR1-/- 
mice (Fig. 3-4B, left panels). Moreover, IFN-γ production was also significantly reduced in non-
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specific CD4 T cells in pLN and lung of IFNαR1-/- mice after PMA+Ionomycin stimulation (Fig. 
3-4B, right panels).  
The mechanism of how IFNαR signaling in non-specific cells impact CD4 T cell expansion or 
Th1 differentiation could be evaluated in future using a model, where Rag-/- bone marrow is 
mixed with IFNαR1-/- bone marrow and transferred to lethally-irradiated IFNαR1-/- hosts. In this 
case, T cells will be exclusively IFNαR-deficient, but APCs will be both WT and IFNαR 
deficient. Mice could then be immunized with SEA, LPS and anti-CD134, followed by the 
analysis of Vβ3+ T cell expansion and Th1 differentiation. This will tell us, if IFNαR signaling 
from Rag-/- bone marrow could rescue the T cell expansion and Th1 differentiation in IFNαR1-/- 
hosts.  
Additional studies will be required to understand, if IFNαR signaling promotes CD4 T cell 
expansion by impacting T cell proliferation [142] or preventing T cell death to increase their 
survival [48]. IFNαR signaling could also impact T cell expansion indirectly by promoting the 
maturation of DCs; by enhancing the expression of MHC-II and costimulatory molecules [277] 
to prime the T cells optimally. It is important to note that, IFN-γ production in specific CD4 T 
cells was reduced in pLN and liver of IFNαR1-/- mice (Fig. 3-4B) that correlates with reduced 
CXCL9 and CXCL10 levels in serum of these mice (Fig. 3-7C). This could mean that, IFNαR 
signaling impacts specific CD4 T cell expansion indirectly by inducing chemokine’s CXCL9 and 
CXCL10 through IFN-γ production.   
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(III) Chemokine CXCL9 plays a significant role in promoting CD4 T cell accumulation in 
lymphoid as well as non-lymphoid tissues 
Before evaluating, if IFNαR signaling promotes T cell accumulation through induction of 
chemokines, CXCL9 and CXCL10, we analyzed if it enhances the expression of chemokine 
receptor CXCR3 on specific CD4 T cells. Previous study from our lab showed that, LPS 
induced TRIF signaling enhanced the CXCR3 expression on specific CD4 T cells in pLN and 
liver, which could explain the T cell migration to peripheral tissue of liver [20]. Our results show 
that, IFNαR1 blockade reduced the accumulation of CXCR3+ specific (Fig. 3-5, let panel) as 
well as non-specific CD4 T cells (Fig. 3-5, right panel) in pLN, however IFNαR signaling 
influenced the accumulation of only specific CD4 T cells in pLN (Fig. 3-2C), but not of non-
specific CD4 T cells (not shown). IFNαR blockade also did not influence the accumulation of 
CXCR3+ specific T cells in liver and lung. Therefore, increased migration of CXCR3+ CD4 T 
cells in pLN, could not explain how IFNαR signaling promotes CD4 T cell expansion in liver 
and lung. In line with this, we saw that CXCR3 receptor was functional on specific CD4 T cells 
after IFNαR blockade, since chemokines, CXCL9 and CXCL10 were able to promote their 
migration in a chemotaxis assay (Fig. 3-6). This suggested that, IFNαR signaling might impact 
the expression CXCR3 ligands rather than CXCR3 expression. Indeed, we saw that CXCL9 
and CXCL10 expression were significantly reduced in the absence of IFNαR signaling (Fig. 3-
7C). Moreover, LPS induced TRIF signaling was required for CXCL9 production (Fig. 3-7D, left 
panel), suggesting that LPS-TRIF mediated CD4 T cell accumulation to liver and lung in 
previous studies [20], could be a result of enhanced CXCL9 production in this tissues.  
When we evaluated, the role of these chemokine’s in promoting T cell accumulation, we saw 
that CXCL9 promoted significant T cell accumulation in the pLN and liver (Fig. 3-8A), whereas 
	  120	  
	  
CXCL10 did not significantly impact the T cell accumulation (not shown). This could have been 
due to incomplete blockade of CXCL10, as IFNαR signaling induced higher levels of CXCL10 
in our vaccine model (Fig. 3-7C, rightmost panel). Perhaps, blocking CXCL10 with higher 
concentration of mAb in future could help ascertain if CXCL10 impacts the T cell accumulation 
similar to CXCL9. It will also be interesting to analyze if combined blockade of CXCL9 and 
CXCL10 could impact T cell accumulation more profoundly, since it was recently shown that 
collaboration between CXCL9 and CXCL10 is required to promote T cell-DC interaction and 
localization of T cells to LN periphery near the pathogen infected cells to allow their Th1 
differentiation [197]. However, in our vaccine model, CXCL9 or CXCL10 did not impact Th1 
differentiation (not shown) probably since our vaccine employs CD134 agonist, which under 
appropriate conditions is known induce Th1 differentiation [17, 239], and could rescue the 
cytokine secretion after CXCL9 or CXCL10 blockade.  
To further evaluate the mechanism of how CXCL9 promotes T cell accumulation, we analyzed 
if it enhances the migration of CXCR3+ specific CD4 T cells and saw that CXCL9 did enhance 
accumulation of CXCR3+ specific T cells in pLN (Fig. 3-8B), however it did not do so in liver 
and lung (not shown). If CXCL9 would have impacted T cell migration from pLN (where T cells 
initially mount an immune response) to the liver and lung, reduced number of T cells in liver 
and lung after CXCL9 blockade, would have resulted in increased T cell numbers in the pLN, 
but that was not the case. Thus CXCL9 does not seem to impact CD4 T cell accumulation 
through increased T cell migration. It is possible that CXCL9 recruits other CXCR3 expressing 
cells such as NK cells [189] and pDC’s [330] which may produce IFN-γ in response to type I 
IFN to further enhance CXCL9 production, creating a feed forward loop to promote CD4 T cell 
	  121	  
	  
accumulation. We haven’t analyzed if CXCL9 impacts accumulation of these cells in our model 
and it could be evaluated in the future studies.  
Another possibility is that, CXCL9 directly acts on T cells to enhance their proliferation, 
however, we did not find any significant difference in Ki67 expression of specific CD4 T cells, 
with or without CXCL9 blockade (not shown). CXCL9 could work by inhibiting the T cell death 
and promoting their survival, however the challenge in this regard is to detect dead specific T 
cells in vivo that have not bound CXCL9. However, it could be analyzed in future by staining 
specific CD4 T cells with annexin V or analyzing the expression of Bcl-xL and Bcl-2 (anti-
apoptotic proteins) in specific T cells after treatment with anti-CXCL9 or control Ab.  
Overall our results show, that CXCL9 plays a dominant role in promoting T cell accumulation in 
lymphoid (pLN) and non-lymphoid tissue (liver and lung) and this was seen in spite of no 
difference in the surrounding levels of type I IFN. Our future studies will focus on 
understanding the mechanism of how CXCL9 impacts T cell accumulation. 
 
(IV) Combining poly I:C with CD134 agonist promotes long lasting Th1 immunity 
As discussed before, for fighting against infectious diseases such as HIV, TB and malaria as 
well as in cancer, both Th1 and CD8 T cell immunity is important. Poly I:C’s ability to induce 
both Th1 and CD8 T cell response makes it an attractive vaccine adjuvant [21, 22, 58, 331]. 
Recently, few studies using combinatorial approaches showed that, combining poly I:C with a 
potent costimulatory molecule CD40 promotes enhanced effector CD4 and CD8 T cell 
responses which provide protection in several infectious diseases [201, 202, 204, 205, 313] as 
well as tumor models [314-316]. Subsequent reports indicated that the synergistic CD4 T cell 
response induced by poly I:C and anti-CD40 is dependent on the expression of CD134L and 
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CD70 on CD8+ DC’s [206]. However, CD134L was found more crucial in comparison to CD70 
in enhancing the CD4 T cell response to poly I:C and anti-CD40 immunization. It was shown 
later in subsequent studies that poly I:C induced IFNαR signaling enhances CD134L 
expression on CD8+ DC’s [27]. Therefore, we evaluated if poly I:C can be directly combined 
with CD134 agonist to promote enhanced CD4 T cell expansion and Th1 differentiation similar 
to poly I:C and anti-CD40 combination. Our results show that combining Ag with poly I:C and 
anti-CD134 promotes enhanced CD4 T cell expansion (Fig. 4-1B) and Th1 differentiation (Fig. 
4-2B) during primary immune response and promotes the generation of long lasting effector 
memory CD4 T cells (Fig. 4-5 and 4-6). Importantly, the enhanced CD4 T expansion and Th1 
differentiation induced by poly I:C and anti-CD134 combination was dependent on IFNαR 
signaling. Poly I:C was the main source of type I IFN in this combination (Fig. 4-1A), whereas 
anti-CD134 induced minimal levels of type I IFN. We however do not know the cellular source 
of type I IFN and whether poly I:C acts through TLR3 or MDA5 signaling pathway. It will be 
interesting to analyze the specific role of these signaling pathways in enhancing CD4 T cell 
immunity during poly I:C and anti-CD134 vaccination. 
Similar to our results, a recent study showed that addition of CD134 agonist to trivax vaccine, 
(a vaccine combining peptide Ag’s with poly I:C and anti-CD40) enhances the long-lasting 
effector CD4 T cell response [315]. However, unlike our study, their results show that addition 
of anti-CD134 to trivax, does not enhance the primary CD4 T cell response, but rather prime 
and boost immunization with anti-CD134 and trivax enhances the long-term effector CD4 T cell 
response. The anti-CD134 mAb they have used in their study, is derived from rat (as used in 
our model) and could generate antibodies in mouse with repeated prime and boost 
immunization, however they did not address this issue. They also have used higher dose of 
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anti-CD134 Ab (200 µg) to generate long-term effector CD4 T cell response, whereas our 
results show that, as less as of 7 µg of anti-CD134 Ab could be combined with poly I:C to 
enhance both short-term and long-term CD4 T cell response. It will be important in future, to 
compare within the same experiment, how single immunization with Ag+poly I:C+anti-CD134 
and Ag+poly I:C+anti-CD40+anti-CD134 impacts primary and memory CD4 T cell response, to 
accurately ascertain if the addition of anti-CD40 to poly I:C and anti-CD134 used in our model 
can be beneficial in providing optimal CD4 T cell immunity.  
It is important to note that, unlike poly I:C and anti-CD134 combination, LPS induced IFNαR 
signaling was not essential for generation of effector memory CD4 T cells in Ag, LPS and anti-
CD134 vaccine combination (Fig. 4-7). Rather inhibition of IFNαR signaling during early T cell 
priming resulted in slight increase in CD4 T cell expansion and Th1 differentiation during the 
recall response. The dispensable role of type I IFN during LPS and anti-CD134 immunization, 
whereas poly I:C’s dependence on it for generation of CD4 Th1-type cells could be a result of 
higher levels of type I IFN induced by poly I:C, through activation of both TLR3 and MDA-5 
pathways, in comparison to LPS, which activates only TLR4-TRIF pathway. 
 
(VI) CD134 stimulation relies on IFNαR signaling to promotes optimal Th1 differentiation 
Our results, demonstrate that CD134 costimulation in specific T cells, requires IFNαR signaling 
to promote CD4 T cell expansion and Th1 differentiation in the spleen (Fig 4-3 and 4-4). 
CD134 signaling is been targeted in several preclinical cancer trials to promote enhanced 
generation of effector CD4 and CD8 T cells. Hence, understanding the mechanism of how 
CD134 costimulation induces IFNαR signaling to promote CD4 T cell expansion and Th1 
differentiation is important. There are few possibilities that could be evaluated. (1) CD134 
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agonist mAb targeted to CD4 T cells could bind through its other end to the FcγRs expressed 
on innate cells such as APCs to promote release of type I IFN. It has been shown before with 
monocyte derived DC’s that simultaneous binding of antibodies targeting inhibitory FcγRs and 
binding of IgGs from human plasma to the activating FcγRs promote the induction of genes 
downstream of type I IFN [332]. To understand if anti-CD134 mAb binds to the Fc receptor to 
trigger type I IFN release, we could evaluate if Fc less anti-CD134 mAb results in reduced type 
I IFN secretion or impacts CD4 T cell responses in vivo distinctly in comparison to Fc receptor 
bearing anti-CD134 mAb (2) Additionally, CD134 expression on T cells could also regulate 
IFNαR expression on them, so that the minimal levels of type I IFN, induced during Eα and 
anti-CD134 immunization bind to the enhanced levels of IFNαR1 expressed on WT T cells and 
activate the signaling.  
Understanding, how CD134 costimulation triggers IFNαR signaling could help evaluate in 
future if targeting CD134 in cancer models results in optimal effector CD4 T cell response and 
anti-tumor immunity or would result in unwanted side effects due to excessive induction of type 
I Interferon induced Th1-type effector cytokines. 
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Fig 5-1. IFNαR1 signaling in both Ag-specific and non-specific cells is required to 
promote specific CD4 T cell response during Ag, LPS and anti-CD134 
immunization. (1) During immunization with LPS and anti-CD134, LPS activates TLR4-
TRIF pathway to induce type I IFN (IFN-β). (2) Type I IFN activates the IFNαR signaling in 
specific CD4 T cells as well as non-specific cells of the host (unknown). (3) IFNαR 
signaling in specific CD4 T cells promotes Ag-specific CD4 T cell expansion in pLN and 
liver, whereas signaling in non-specific cells of host is required for specific T cell 
expansion in liver and lung (4). Furthermore, IFNαR signaling in non-specific cells of the 
host, triggers IFN-γ production from specific (pLN, liver) as well as non-specific CD4 T 
cells (pLN, lung). Ours is the first study evaluating how LPS induced IFNαR signaling in 
Ag-specific T cells versus non-specific cells impact the CD4 T cell response. 
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Figure 5-2. LPS induced IFNαR1 signaling triggers CXCL9 production to promote 
Ag-specific CD4 T cell accumulation in lymphoid as well as non-lymphoid tissues.     
(1) During immunization with Ag, LPS and anti-CD134, LPS activates TLR4-TRIF 
pathway to promote type I IFN (IFN-β) production. (2) IFN-β binds to the IFNαR and 
activates IFNαR signaling (3) IFNαR signaling promotes the release of chemokine 
CXCL9, which could also be induced indirectly through IFN-γ induced during LPS and 
anti-CD134 immunization (data not shown). (4) Following this, CXCL9 may bind CXCR3 
on activated CD4 T cells and promote their accumulation in pLN, liver and lung. The 
mechanism behind this is unknown. However, it suggests that CXCL9 could be targeted 
in T cell vaccination strategies to promote Ag-specific CD4 T cell accumulation in both 
lymphoid and non-lymphoid tissues. 
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Figure 5-3. Ag, poly:IC and anti-CD134 induced maximal CD4 T cell expansion and 
Th1 differentiation is dependent on IFNαR1 signaling, however CD134 costimulation 
also requires IFNαR1 signaling to promote CD4 T cell response. (1) During poly I:C 
and anti-CD134 immunization poly I:C could trigger type I IFN, (IFN-β) induction through 
either TLR3 or MDA-5 signaling pathways. (2) Released type I IFN, then activates IFNαR 
signaling, which together with CD134 costimulation promotes maximal CD4 T cell 
expansion and Th1 differentiation in spleen and liver during both primary and recall 
response. (4) CD134 costimulation in T cells also induces minimal levels of type I IFN (IFN-
β) which promotes CD4 T cell expansion and Th1 differentiation through an unknown 
mechanism. The mechanism of how CD134 cositmulation triggers IFNαR signaling needs 
to be evaluated in future, for efficient targeting of CD134 in preclinical tumor models. 
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